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1 ABSTRACT 
Gemcitabine, an anticancer agent, is currently in clinical use for the treatment of several types 
of cancer. Unfortunately, gemcitabine is rapidly metabolised with a short plasma half-life and 
its cytostatic action is strongly exposure-time dependent. In order to achieve the required 
concentration over sufficient periods of time, repeated application of relatively high doses is 
required. This, in turn, leads to dose-limiting systemic toxicity. In order to improve both the 
efficiency and the toxicity profile of gemcitabine the use of liposomes appears promising. In 
literature, only a few attempts to entrap gemcitabine within liposomes are found, however 
none of these liposomal formulations has reached clinical practice. In this study, an 
ammonium sulphate gradient was tried for active loading of gemcitabine into liposomes.  
 
Firstly, unsaturated egg phosphatidyl choline liposome dispersion was prepared with 
ammonium sulphate as hydration medium by the hand shaken method followed by filter 
extrusions with decreasing filter pore sizes down to 0.1 µm. Then, a transmembrane 
ammonium sulphate gradient was generated by removing extra-liposomal ammonium 
sulphate by size exclusion chromatography. Quantitative determination of the ammonium 
sulphate concentration, both outside and inside the liposomes, via electric conductivity 
measurement revealed that a gradient of external to internal ammonium sulphate of about 1:58 
was achieved.  
 
Secondly, the liposomes were loaded with gemcitabine by incubation at different conditions. 
Among the loading conditions tested, a total loading time of 24 hours including heating for 2 
hours at 60 ˚C seemed advantageous in achieving efficient loading. A higher starting 
concentration of gemcitabine resulted in enhanced loading efficiency, calculated on a molar 
basis. Comparing these results to a vesicular phospholipid gel passive loading technique, the 
active loading technique resulted in a gemcitabine:lipid ratio of about 1:20 versus 1:140 for 
the vesicular phospholipid gel loaded liposomes. Unfortunately, the actively loaded liposomes 
revealed poor storage stability with 80 % leakage after 24 hours. Further studies are needed in 
order to optimise loading and stability of the liposomes. 
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AUC Area under the curve 
CI Contraindication 
conc Concentration 
dFdC difluorodeoxycytidine, gemcitabine 
dFdCDP difluorodeoxycytidine diphosphate 
dFdCTP difluorodeoxycytidine triphosphate 
dFdU difluorodeoxyuridine  
E-80 Unsaturated egg phosphatidyl choline 
EE Encapsulation efficiency 
HPLC High performance liquid chromatography 
LUVs Large unilamellar vesicles 
MLVs Multi lamellar vesicles 
MW Molecular weight 
NSCLC Non-small cell lung cancer 
PC Phosphatidyl choline 
PCS Photon correlation spectroscopy 
RP-HPLC Reversed-phase high performance liquid chromatography 
SEC Size exclusion chromatography 
SD Standard deviation 
SUVs Small unilamellar vesicles 
t½ Elimination half life 
UV Ultraviolet 
VPG Vesicular phospholipid gel 
v/v Volume ratio 
w/w Weight ratio 
χ2 Chi square  
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3 INTRODUCTION 
According to the Cancer registry of Norway, 24 434 new cases of cancer were detected in 
2004. Among males prostate cancer was most frequent with 3818 new cases, whereas breast 
cancer was most frequent among females with 2754 new detected cases. With more than 10 % 
of all new cases for males, the lungs are one of the most common cancer sites and since the 
seventies, lung cancer has been increasing among females as well. Bladder cancer is a 
common type of cancer among males. (1) The current therapy for cancer consists mainly of 
three approaches; radiotherapy, surgery and chemotherapy with antineoplastic drugs. 
 
The ideal prototype of an antineoplastic drug should display anti tumour activity by targeting 
and damaging cancer cells without causing adverse effects or toxicity to healthy cells. Until 
now there are no such drugs. A drive has thus emerged for developing new antineoplastics or 
improving the efficacy and the toxicity profile of already existing cytotoxic agents. 
Formulations based on liposome technology are one strategy in approaching this requirement. 
 
3.1 Liposomes 
Liposomes are spherical vesicles composed of lipid bilayers arranged around a central 
aqueous core. They can be composed of natural constituents such as phospholipids and may 
mimic naturally occurring cell membranes. Liposomes have the ability to incorporate 
lipophilic and amphiphilic drugs within their phospholipid membrane or they can encapsulate 
hydrophilic compounds within the aqueous core as shown in Figure 1. Liposome formulations 
can therefore increase safety and efficiency in reaching the site of action. (2-4) 
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Figure 1: A schematic representation of incorporation and encapsulation of drugs into a liposome (Figure 
reprinted with permission from Elsevier. (3))  
 
3.1.1 Liposome composition 
A phospholipid exists of a hydrophilic head group and lipophilic tails. The polar head can be 





Figure 2: A schematic representation of a phospholipid (Figure taken with permission from: 
http://www.bioteach.ubc.ca/Bio-industry/Inex/. Artist: Jane Wang) 
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Phosphatidyl choline (PC), the primary lipid used in liposomes, belongs to the group of 
phosphodiglycerides, which are naturally occurring phospholipids. The amphiphilic PC is 
composed of the phosphocholine, a hydrophilic head group, linked to two lipophilic acyl 




Figure 3: Chemical structure of phosphatidyl choline 
 
 
Since PC’s are not water soluble they self-assemble upon contact with aqueous media 
orienting their hydrophobic chains away from the aqueous media. They orient in a membrane 
like structure reducing the interaction between the hydrophobic fatty acids and the aqueous 
medium (Figure 4). Liposomes form spontaneously from lipid bilayers under the influence of 





Figure 4: Phospholipid bilayer (Figure taken with permission from: http://www.bioteach.ubc.ca/Bio-
industry/Inex/ Artist: Jane Wang) 
 
 
PC can be produced chemically, though it is easily and inexpensively derived naturally from 
egg yolk and soybeans. (4) PC is zwitterionic and produces chemically inactive liposomes 
without a net charge. (2, 4) Hence, it is a widely used lipid. (4)  
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Liposomal membranes can exist in different phases depending on the temperature. The 
membranes physical state is changing from a tightly organised gel phase to a more moveable 
liquid-crystal phase with increasing temperature. This results in more flexible and permeable 
bilayers. The chain length and the degree of saturation of the alkyl chains determine the phase 
transition temperature. (2, 4) Egg PC has a phase transition temperature between -15 and -7 
˚C. (4) 
 
A liposomal membrane composed of egg PC allows small neutral molecules to diffuse 
through the membrane. However, in the combination with other lipids or with cholesterol the 
stability is improved by making the membrane more tightly organised. This tighter packed 
membrane will reduce leakage. Cholesterol is a steroid and reduces the movement of the long 




Figure 5: Chemical structure of cholesterol 
 
 
3.1.2 Relevance of liposome size 
The sizes of liposomes can be divided into large, intermediate and small and display different 
features depending on their size. (2) Even though large liposomes have the largest entrapped 
volume they are not ideal for intravenous administration since they are too big for escaping 
the macrophages during circulation in the blood pool. Intermediate liposomes can escape 
macrophages and stay in the blood pool long enough for reaching targets close to the 
circulation. Small liposomes have the smallest captured volume and a shorter circulation time 
compared to intermediate liposomes due to capillary extravasation. However, this gives them 
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the unique ability to reach targets outside the blood pool such as solid tumours. (2) One 
possible classification according to size is listed in Table 1. (4) 
 
 
Table 1: Classification of liposomes according to size. 
 
Liposome classification Size (nm) No of lamellae 
Multilamellar vesicles (MLVs) 100-1000  >5 
Small unilamellar vesicles (SUVs) <100 nm, lowest 
possible size* 
1 
Large unilamellar vesicles (LUVs) >100 nm 1 
*) Varies according to ionic strength, aqueous medium, lipid composition of membrane 
 
 
Liposomes can change in shape during storage of dispersions. There are two different types of 
alterations increasing the size of liposomes, aggregation and fusion. (2) This alters the 
liposomal features. Aggregation is a process where liposomes are linked together without 
breaking the membranes. This process is reversible. However, fusion is an irreversible process 
where liposome membranes are broken and melted together with other liposomes forming 
bigger particles. An increase in size is thus a direct result of a change in shape. 
 
3.1.3 The rationale for using liposomes in chemotherapy 
Intravenous route of administration is considered as the most promising route for liposomal 
formulation. The role of the liposome (containing the drug) is to circulate in the blood in order 
to reach the desired organ or tissue. The liposomal membrane acts as a barrier protecting the 
drug from premature elimination or metabolism. At the same time, the liposome membrane is 
controlling the release of the cytotoxic agent. The liposome carrier may also direct drugs to 
the tumour site. Thereby, the therapeutic window and toxicity profile of drug compounds can 
be improved. (2) 
 
The liposomal accumulation at tumour site is referred to as the enhanced permeability and 
retention effect and is based on dissimilarities of healthy and cancerous tissues. The 
endothelial walls of blood vessels in tumours are leakier than those in healthy tissues because 
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of an increased number of bigger gaps. Thus, small liposomes are able to extravasate and 
penetrate into solid tumours. At the same time, the liposomes stay longer within the tumour 
site since the removal by the lymphatic system is greatly reduced in cancerous tissue. These 
special characteristics of cancerous tissue facilitate an accumulation and retention of small 








3.1.4 Challenges with liposome formulations 
Upon entering the general circulation the liposomes must be able to avoid uptake by 
macrophages. Once plasma proteins adsorb to the liposomal surface the liposomes are easily 
taken up by macrophages resulting in a decrease in liposomal elimination half life (t½). 
Adsorption of plasma proteins to liposomes can be reduced by producing small liposomes 
with rigid uncharged membranes, such as PC and cholesterol. The stability of liposomes can 
also be affected prior to administrating the drug. The shelf life of the product is dependant 
upon the chemical and physical stability. The different components in the final liposomal 
product can interact with each other resulting in degradation. In addition, hydrophilic drugs 
with a low molecular weight (MW) are prone to diffuse through the liposomal membrane, 
reducing the shelf life of the product. In this case a tightly packed membrane is essential. 
Thus, the liposomal membrane composition, i.e. lipid composition and lamellarity is 
important since it together with the physiochemical characteristics of the drug determines the 
retention of the active ingredient within the liposome. (2, 3) 
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3.2 Gemcitabine 
Gemcitabine is a cytotoxic drug available on the market in the freeze-dried form of an 
aqueous solution of the HCl salt known as Gemzar. After reconstitution Gemzar is used for 
intravenous administration as an infusion only.  
 
3.2.1 Therapeutic indications 
Gemcitabine has numerous applications for cancer and is indicated for breast cancer, non-
small cell lung cancer (NSCLC), bladder cancer, ovarian cancer and pancreatic cancer as seen 
from Table 2. (6-9) Gemzar can also be used in patients displaying the following conditions: 
Cancer of the lymph system, the bile ducts, the gallbladder and germ cell tumours of the 
ovaries and testes. (10) 
 
 
Table 2: Therapeutic indications of Gemzar. 
 
Cancer type Combination Stage in cancer 
Breast cancer -2nd line paclitaxel metastatic 
NSCLC – 1st line 
 




IIIA & IIIB (inoperable locally 
advanced), IV (metastatic) 
 
Pancreatic cancer: 1st and 2nd line** NIL II & III (inoperable locally 
advanced), IV (metastatic) 
Bladder cancer cisplatin IV (muscle invasive) 
Epithelial ovarian cancer carboplatin III (locally advanced), IV 
(metastatic) 
*) after failure or CI of anthracycline treatment 
**) for patients previously treated with 5-FU 
 
 
3.2.2 Chemical characteristics 
The chemical name of gemcitabine is 2′-deoxy-2′,2′-difluorocytidine monohydrochloride. 
Gemcitabine, or difluorodeoxycytidine (dFdC), is an antimetabolite cytotoxic. It is a chemical 
analogue to the natural nucleoside deoxycytidine (Figure 7). (6, 11, 12) 
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Deoxycytidine      Gemcitabine 
 
Figure 7: Chemical structure of deoxycytidine and the antimetabolite gemcitabine 
 
 
From Figure 7 it can be seen that two hydrogen atoms of the carbon on the second position of 
deoxycytidine are substituted with two fluoride atoms giving gemcitabine. The pair of 
fluoride atoms is contributing to the low pKa value of 3.58 for the gemcitabine HCl salt due 
to the increased electronegativity. (13) Gemcitabine has a MW of 263.199 g/mol whereas 
gemcitabine HCl has a MW of 299.66 g/mol due to the presence of hydrochloride. 
Gemcitabine HCl is a white to off-white powder soluble in water. (6) 
 
3.2.3 Mechanism of action 
The prodrug gemcitabine is converted intracellularly via deoxycytidine kinase to 
difluorodeoxycytidine monophosphate, which is further converted to two active metabolites, 
dFdCDP and dFdCTP, di– and triphosphate, respectively. Firstly, dFdCDP inhibits the 
catalysing enzyme ribonucleotide reductase resulting in a reduced amount of deoxynucleotide, 
deoxycytidine triphosphate (dCTP), available for DNA synthesis. Secondly, dFdCTP 
competes with dCTP for incorporation into DNA. Incorporating dFdCTP results in chain 
termination after the further addition of one more nucleotide and thus to apoptosis. Thus dFdC 
affects the synthesis phase of cell metabolism in two different ways and exhibits a self- 
potentiating effect. (6, 8, 11, 12, 14) 
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DFdC is rapidly metabolised in the blood, liver, kidneys and other tissues. Gemcitabine 
displays a short t½ ranging from 8 to 17 minutes. Less than 10 % is excreted unchanged in the 
urine, however large amounts of its primary metabolite, difluorodeoxyuridine dFdU were 
detected. (12, 15) Only a small portion of dFdC will convert into dFdCDP and dFdCTP (6) 
whereas 91-98 % of administered dFdC will turn into the inactive difluorodeoxyuridine 
(dFdU). (12, 15) 
 
3.2.5 Toxicity  
The cytotoxic activity of gemcitabine in vivo is schedule dependent. (6, 12, 15) This means 
the activity and the toxicity are related to the dose given and the dosage interval of the 
treatment. The problem with Gemzar is its short plasma t½ and its quick metabolism into 
dFdU followed by elimination from the body. Therefore high doses of dFdC are required in 
order to achieve sufficient cytotoxic concentrations of dFdCTP. (13, 15, 16) Due to the 
narrow therapeutic window, high administered doses increase the possibility of toxicities and 
concentration dependent side effects for patients. According to clinical studies, the primary 
dose limiting toxic effect is myelosuppression; neutropenia, leucopenia, anaemia and 
thrombocytopenia. In addition, together with other side effects, such as hepatic abnormalities, 
nausea and vomiting, 10 % of patients ceased treatment. (12) 
 
3.2.6 Approaches for improving formulation 
Some attempts, including the use of liposomes, have been tried in order to overcome the 
problems seen with Gemzar. DFdC is uncharged at physiological pH and is a low MW 
molecule, which will make it diffuse quickly through the liposomal membrane. (15) 
Gemcitabine has successfully been entrapped within liposomes, however it leaked out of the 
vesicles very quickly. In addition, dFdC appears to induce degradation of the liposomal 
membranes. (17) In order to avoid these problems Gemzar was encapsulated into vesicular 
phospholipid gel (VPG) reaching an encapsulation efficiency (EE) of 33 % and a shelf life 
above 14 months. A pilot study proved the formulation encapsulating dFdC into VPG had 
biphasic elimination (due to free dFdC and encapsulated dFdC) resulting in an increased 
concentration in plasma compared to Gemzar. (15) 
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Despite the increased potency of the VPG formulated gemcitabine, GemLip, it also revealed 
increased toxicity. The increased toxicity was most likely due to the prolonged and fractioned 
administration of gemcitabine. However, GemLip consists of 33 % encapsulated dFdC and 67 
% of extra-liposomal dFdC. This amount of free dFdC will exhibit the same rapid metabolism 
and the same toxicities as conventional Gemzar.  
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4 AIM 
The primary aim of this study was to investigate, whether an active loading approach can be 
used for encapsulating gemcitabine, an anticancer agent, into liposomes. Active loading was 
tried as an alternative loading approach for dFdC due to the positive literature reports. 
Literature indicated that drugs could efficiently be encapsulated within liposomes and that 
these liposomes were especially stable during storage. The active loading approach may also 
be suited to reduce the amount of free dFdC outside liposomes compared to the VPG method. 
A high amount of dFdC in the aqueous compartment of liposomes with a negligible amount of 
dFdC outside the liposomes could increase the potency and decrease the toxicity associated 
with Gemzar treatment. 
 
The active loading method is carried out by using a transmembrane gradient approach. An 
ammonium sulphate pH gradient has shown to facilitate loading of drugs into the liposomes 
and in certain cases also induce aggregation (precipitation) of the drug inside the vesicle.  
 
Upon establishment of an active loading method two secondary aims were exploited. The first 
goal was to optimise dFdC-loading into liposomes displaying an ammonium sulphate gradient 
and the second goal was to investigate the stability of active loaded liposomes by checking the 
encapsulated amount of dFdC within the liposomes during storage. 
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Table 3: Lipids 
 
Name of lipid Batch Producer 
Cholesterol recrystallised in methanol 
(18) 
01107101 Croda chemicals Plc, Goole, 
UK 
Unsaturated egg phosphatidyl choline  
E-80 













N/A 235474-5G/ 08202ED Sigma Aldrich, Chemie 
GmbH, Steimheim, 
Germany 




99.999 % 204501-250G/0681OPB Sigma Aldrich, Chemie 
GmbH, Steimheim, 
Germany 
Chloroform 99.8 % K30427544 211 Merck, KGaA, Darmstadt, 
Germany 
D(+)Glucose  N/A 607425208 Ferak Berlin GmbH, 
Berlin, Germany 
D(+)Glucose  Ph Eur 05J100011 Prolab, Austin, USA 
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Ethanol 96 % N/A Arcus Kjemi AS, Vestby, 
Norway 
Gemcitabine  
In the form of the drug product 
Gemzar, which also contains 
mannitol, sodium acetate, 
hydrochloric acid and sodium 
hydroxide 
N/A FF5K29G, FF4L39J Eli Lilly and Company, 
Indianapolis, USA 
Hydrochloric acid N/A 60169847 Merck, KGaA, Darmstadt, 
Germany 




99.5 % A116773834 Merck, KGaA, Darmstadt, 
Germany 
Sephadex G-50 N/A 17004301/250321 Pharmacia Biotech, AB, 
Uppsala, Sweden 
Sephadex G-50 N/A 51-1858-00-AA/250321 Pharmacia Biotech, AB, 
Uppsala, Sweden 
Sodium Chloride 99.5 % K31137233236 BDH Laboratory Supplies, 
England, UK 
Sodium Hydroxide 98- 
100.5 % 
B252082 830  Merck, KGaA, Darmstadt, 
Germany 
Triton X-100 N/A 053K0027 Sigma Aldrich, Chemie 
GmbH, Steimheim, 
Germany 
Triton X-100 97–105 % L667143 221 Merck, KGaA, Darmstadt, 
Germany 
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Table 5: Equipments 
 
Equipment Type Manufacturer 
Conductivity meter Conductivity Hand-held 
meter LF340,  
Standard Conductivity cell 




Dialysis membrane Dialysis Tubing-Visking 
Size 9 Inf Dia 36/32” – 28.6 
nm: 3 
Medicell International Ltd, 
London, UK 
Filter extruder – Hand 
driven 
LiposoFast Avestin Inc, Ottawa, Canada 
Filter extruder – Pressurised 
air driven 
Maximator MSF 27 LS-02-
K 
Schmidt, Kranz & Co 
GmbH, Velbert, Germany 
Gel filtration column 
 
Gel column, with Sephadex 
G-50  
Produced in-house 




Gaulin APV, Micron Lab 
40, 99L15450 








Waters 2695 Separations 
module 
Millennium32 Version 4.00 
 
Waters 2487 dual λ 
Absorbance Detector 
LiChrospher 60, RP- Select 







Merck, KGaA, Darmstadt, 
Germany 
Incubator TV10B 677491 Memmert GmbH + Co KG, 
Schwabach, Germany 
 
GEMCITABINE CONTAINING LIPOSOMES 
MATERIALS AND METHODS 
 
HILDE GRAVEM 2006  
21 
Mini column separation LiChrolut incl. PTFE Frits 
and 8 ml glass columns 
Merck, KGaA, Darmstadt, 
Germany 
pH meter 744 pH Meter Metrohm Ion 
Analysis 
Metrohm Ltd, Herisau, 
Switzerland 
Photon Correlation 
Spectroscopy - PCS 
Submicron Particle Sizer 
Model 370 (CW 370) 
Nicomp Particle Sizing 
systems, Santa Barbara, 
USA 
Rotavapor Büchi Rotavapor R-124 Büchi labortechnik AG, 
Flawil, Switzerland 
Scales Sartorius LP 620S Sartorius AG, Goettingen, 
Germany 
Stirrer RTC basic B,  
IKA color squid 
IKA Werke GmbH & 
Co.KG, Staufen, Germany 
Centrifuge Biofuge Stratos Kendro Laboratory products 
GmbH, Hanau, Germany 
Solid phase extractor Supelco Visiprep Sigma Aldrich, Chemie 
GmbH, Steimheim, 
Germany 
Ultrasonic cleaner Bransonic Ultrasonic 
Cleaner 1510E-MT 
Branson Ultrasonic 
Corporation, Danbury, USA 
Vacuum controller Büchi Vacuum Controller  
B-721 
Büchi labortechnik AG, 
Flawil, Switzerland 
Vacuum machine  Büchi Vacuum Controller  
B-721 
Büchi labortechnik AG, 
Flawil, Switzerland 
Vacuum pump Millipore Vacuum Pump 
XF5423050 
Millipore S.A., Molsheim, 
France 
Water bath Büchi Waterbath B-480 Büchi labortechnik AG, 
Flawil, Switzerland 
Filters: 





Corning 430513, 500 ml 
bottle top filter w/45 mm 
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For organic HPLC eluent 
filtration 
 
For aqueous HPLC eluent 
filtration 
Millipore Isopore Membrane 
filters:  
0.8µm batch no:R2NN87234 






polyamide 0,2µm filter batch 
no: 0700 25007 9904663, 
Nitrocellulose VCWP 0.1 
µm filter: lot no: H5JN 
02154 








Sartorius AG, Goettingen, 
Germany  
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5.3 Media and solutions 
Ammonium sulphate solution: 
• Used as hydration medium in MLV production  
 
120 mM ammonium sulphate solution: 
I Ammonium sulphate:    1.584 g 
II Distilled water:    ad 100.0 ml 
 
Glucose solution: 
• Used as diluting agent in PCS 
• Used as separation medium in gel chromatography 
• Used as hydration medium in VPG production  
 
50 g/L glucose solution: 
I Glucose:     50.0 g 
II Distilled water:    ad 1000.0 ml 
 
20 % Ethanol: 
• Used as preservative for Sephadex G-50 gel during storage 
 
20 % v/v ethanol:  
I 96 % ethanol:     20.0 ml 
II Distilled water:    80.0 ml 
 
Triton solution: 
• Used for dissolving liposomes 
 
10 % v/v triton solution: 
I Triton X-100:     100.0 ml 
II Distilled water:    ad 1000.0 ml 
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Saturated sodium chloride solution: 
• Used for preparing ion exchange column 
 
Saturated sodium chloride: 
I Sodium chloride:    200.0 g 
II Distilled water:    ad 500.0 ml 
 
The solution was heated close to its boiling point before it was filtrated into a flask for 
storage.  
 
9 mg/ml sodium chloride solution: 
• Used as hydration medium for gemcitabine 
 
9 mg/ml sodium chloride: 
I Sodium chloride:    450.0 mg 
II Distilled water:    ad 500.0 ml 
 
Phosphate buffer: 
• Used as dilution media for gemcitabine in standard curve  
• Used as dilution agent for HPLC measurements 
 
25 mM phosphate buffer (pH 6.9): 
I Potassium dihydrogen phosphate:  6.805 g 
II Distilled water:    ad 2000.0 ml 
III Hydrochloric acid for pH adjustment q.s. 
III Sodium hydroxide for pH adjustment q.s. 
 
Mobile phase for HPLC analysis: 
 
Phosphate buffer with methanol v/v: 
I Phosphate buffer:    92.5 ml 
II Methanol:     7.5 ml 
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5.4 Preparative methods 
5.4.1 Preparation of multi lamellar vesicles (MLVs) 
MLVs were prepared according to the following methods: 
 
5.4.1.1 Egg-PC raw dispersion: Hand shaken method: 
10 % w/w E-80 in 120 mM ammonium sulphate solution: 
I E-80:      10.0 g 
II 120 mM ammonium sulphate:  90.0 g 
The raw dispersion was gently stirred using a magnetic stirrer for approximately 2 hours until 
E-80 was dispersed. 
 
5.4.1.2 Egg-PC/Cholesterol dispersion: Film method: 
10 % w/w E-80/Cholesterol in 120 mM ammonium sulphate solution (55 mol % E-80 and 45 
mol % cholesterol): 
I E-80/cholesterol:    24.3 g 
II 120 mM ammonium sulphate:  ad 243 g 
The film method was carried out according to New, Lasch, Weissig and Brandl. (5, 19) 
 
• Lipids were dissolved in chloroform: methanol in the ratio 2:1 by hand shaking 
• The round bottom flask containing the resulting solution was attached to rotavapor and 
placed in a water bath at approximately 55 to 60 ˚C with a decreasing pressure for 
approximately 15 minutes. 
•  The resultant film was further dried at a pressure of 200 hPa for 1.5 hours followed by 
a decrease in pressure to 50 hPa for another 3 hours. 
• The hydration medium (120 mM ammonium sulphate solution) was heated up to 55 to 
60 ˚C and added to the film. The round bottom flask was shaken vigorously before 
placing it back in the water bath and attaching it to the rotavapor (without vacuum) 
until the film was completely dispersed. 
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5.4.2 Reduction of liposome size 
Preparation of liposomes results in MLVs with a wide particle size distribution. In order to 
achieve more homogenous sizes of the liposomes, filter extrusions were executed. 
 
5.4.2.1 Filter extrusions 
Filter extrusion involves the process of squeezing the liposome dispersion through pores of 
polycarbonate filters of decreasing pore sizes by applying pressure. As a result, the liposomes 
will break and form smaller sized liposomes. (2) Liposome membranes deform when passing 
through the filter pores. The deformability is reduced in liposomes containing cholesterol, 
which results in decreased rate of extrusion. However, increasing the temperature facilitates 
the extrusions. (20) 
 
Hand driven filter extrusions are suitable for small-scale filter extrusion due to limited syringe 
volume whereas machine driven filter extrusions allows larger volumes and are thereby 
appropriate for large-scale filter extrusions.  
 
Filter extrusion by hand 
Hand driven filter extrusion was performed using LiposoFast (Picture 1). This method 
involves the transfer of the liposome dispersion from a 1 ml syringe through a filter holder 
containing Millipore Isopore filters into a second syringe. This is achieved by applying 
manual pressure. The transfer of liposomes is repeated five times in order to achieve a more 
uniform liposome size. In addition, the uneven number of extrusions will prohibit the 
liposome dispersion to end up in the initial syringe and thus reduce the contamination with 
liposomes of larger sizes. Filter extrusion was performed consecutively using filters with 
decreasing pore sizes of 0.8 μm, 0.4 μm, 0.2 μm and 0.1 μm.  
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Continuous High Pressure Filter Extrusion  
A Maximator, originally described by Schneider, Sachse, Rößling and Brandl, (21) was used 
for the machine driven filter extrusion. Filter extrusions took place upon initiation of air 
pressure (ideally at 300 kPa, but less than 500 kPa). As with the hand extruder, 5 cycles of 
filter extrusion per filter was performed to obtain a more homogenous size distribution of the 
liposome dispersion. Isopore filters with decreasing pore sizes in the same magnitude as for 
the hand driven extrusions were used for the continuous high pressure filter extrusions.  
 
The applied pressure driving the liposomes through the filter varied according to the filter size 
and the speed of the pump. This applied pressure generated a higher pressure over the filter to 
execute the extrusions. Table 6 shows the pressures and the following translating factors. 
 
 




Applied air pressure 
(bar) 
Resulting pressure over 
filter (bar) 
Translation factor 
0.8 0.75 20 26.7 
0.4 0.75 20 26.7 
0.2 0.75 20 26.7 
0.1 1.50 60 40.0 
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5.4.3 VPG production: 
40 % w/w E-80 in 50 g/L glucose: 
I E-80:      12.0 g 
II 50 g/L glucose:    18.0 g 
The VPG was gently stirred for approximately two hours using a magnetic stirrer until E-80 
was dispersed. 
 
VPG was produced for passive loading of gemcitabine into liposomes as described by Moog 
et al. (15) This was done in order to compare the efficiency of active loading to a standardised 
method. 
 
VPG is a gel, hence, not suitable for filter extrusion. Therefore, reduction in liposome size 
was achieved through high pressure homogenisation. 
 
5.4.3.1 High pressure homogenisation: 
The high pressure homogeniser forces the VPG through a narrow valve applying high 
pressure. Liposomes are exposed to local stress due to the pressure drop occurring after VPG 
exits the valve. The decrease in particle size is described by two theories, the cavitation 
phenomenon and the turbulence theory. In brief, in the cavitation theory the liquid cavitates 
because of the large pressure drop when the liquid goes through the valve. When an 
appropriate pressure drop occurs, bubbles burst after leaving the valve, generating shock 
waves resulting in shear forces tearing the dispersion apart. The turbulence theory describes 
the generation of eddies caused by dissipating energy in the liquid. Together with the pressure 
differences, these eddies are responsible for shearing of the droplets. (22) 
 
The VPG was homogenised in a Gaulin APV homogeniser. The gel was placed into the 
homogeniser and a pressure of 70 MPa was applied. The VPG was then collected, and the 
procedure was repeated nine times. (23) 
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5.4.4 Reconstitution of Gemzar 
According to the summaries of product characteristics (SPC) for Gemzar 5.0 ml 9 mg/ml 
NaCl was transferred into the Gemzar vial giving a maximum concentration of 38 mg/ml of 
gemcitabine. (8) 
 
5.4.5 Active loading of gemcitabine into liposomes via a transmembrane ammonium 
sulphate gradient 
Active loading through a pH gradient is a technique based on the membrane permeability of 
the free base of a hydrophilic drug, whereas its charged, protonated form is membrane 
impermeable. The drop in pH is caused by an ammonium sulphate transmembrane gradient 
having liposomes with internal ammonium sulphate surrounded by an ammonium sulphate 
free medium. Encapsulated ammonium ions are in equilibrium with uncharged ammonia and 
protons. The capability to permeate the liposomal membrane is dependent on size and charge 
of the species according to the following relation: NH3>>> H+>> NH4+> SO42-> (NH4)2SO4. 
(24) A shift in equilibrium to the right (Equation 1), thus a reduction in the pH within the 




 Equation 1: NH4+ ⇌ H+ + NH3 
 
 
Simultaneously, the neutral form of the drug, in this case the free base of gemcitabine, is 
expected to diffuse into the vesicle where it becomes protonated, due to the low pH, and thus 
trapped. This decreases the proton concentration within the liposomes, however, more 
ammonia will subsequently be produced and diffuses out of the vesicle increasing the proton 
supply facilitating the drug uptake. (24, 25) 
 
In order to create the gradient, liposome formation is carried out in ammonium sulphate 
solution followed by removal of external ammonium sulphate. The better the removal of 
ammonium sulphate in the outer aqueous phase, the greater the gradient becomes. This was 
executed by size exclusion chromatography (SEC) using Sephadex G50 gel. 50 g/L glucose 
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was used as hydration medium in the column since this concentration is expected to be 
isoosmotic with 120 mM of ammonium sulphate when added to the liposome dispersion. (24) 
 
Based on the amount of substance of encapsulated ammonium sulphate in the liposome 
fraction compared to the amount of substance in the initial liposome dispersion, the 








efficiencyion Encapsulat =  
 
 
The gradient is determined by comparing the concentration of external ammonium sulphate 
([(NH4)2SO4]ext) in the liposome fraction after separation after SEC (see section 5.4.5.1) with 








 ]SO)[(NH Gradient =  
 
 
5.4.5.1 Size exclusion chromatography (SEC) for generation of the ammonium sulphate 
gradient 
Theory: 
Gel filtration is a SEC method separating different particles or substances according to their 
size. A column is filled with a pre-swollen porous gel, completely packing the column. 
Particles diffuse in and out the pores of the gel and therefore pass through the column at 
different speed according to their size or MW. Larger particles pass through the column in a 
faster manner compared to smaller particles due to less diffusion into the matrix. As a result 
different fractions containing different particles can be collected subsequent to the separation. 
(26) 
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Packing of column: 
The gel filtration column was prepared in-house using Sephadex G-50 as gel matrix according 
to the gel filtration handbook from GE healthcare. (26) Sephadex G-50-powder was mixed 
with excess distilled water and placed in a Büchi Waterbath B-480 at 90 °C for one hour in 
order to swell. The gel filtration column was set up with glass wool in the bottom of the 
column to prevent leakage of Sephadex gel matrix. Degassed 50 g/L glucose was used as a 
hydration medium to pack the column with Sephadex gel.  
 
Procedure: 
Three times the column volume of 50 g/L glucose was run through the column before the 
sample was added. (26) During separation continuous amounts of medium were added in 
order for the column to stay wetted. The fractions, containing the different particles, were 
collected and their volume was measured. 
 
5 ml of liposome dispersion was transferred to the column and the fractions were collected. 
Liposomes pass through the column in a faster manner compared to ammonium sulphate 
giving ideally one fraction consisting of liposomes with an internal ammonium sulphate 
solution and 50 g/L glucose as the outer phase. The liposome fraction could easily be 
collected from the column since the fraction appeared turbid. After separation the column was 
washed with 500 ml 50 g/L glucose in order to remove residual ammonium sulphate from the 
gel matrix. (26) During longer breaks, the gel matrix was stored in 20 % ethanol acting as a 
preservative to prevent growth of micro-organisms.  
 
5.4.5.2 Loading compounds into liposomes by ammonium sulphate gradient 
The use of a pH gradient for encapsulation of drugs may reduce problems associated with 
other loading techniques. By applying a transmembrane gradient to the liposomes the drug is 
expected to cross the membrane with an increased trapping efficiency and drug retention as 
compared to other loading techniques. (27) 
 
5.4.5.3 Acridine orange loading 
Acridine orange was used in preliminary experiments for qualitative evaluation of the 
ammonium sulphate gradient. Acridine orange has advantages compared to gemcitabine, 
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which makes it suitable to use as a model. Firstly, acridine orange is not toxic and is therefore 
safe and suitable for preliminary experiments and secondly its orange colour is easy to 
identify visually. 
 
Acridine orange was added to the dispersion after the gradient was established. When loading 
had completed the dispersion was run through the gel column again for separating the fraction 
of free acridine orange from the liposome fraction.  
 
The liposomes containing acridine orange should appear orange and turbid and thus easy to 
collect. Before the fraction of free acridine orange there should theoretically be a small 
colourless fraction. 
 
5.4.5.4 Loading of dFdC 
According to Fenske, Maurer and Cullis, a transmembrane ammonium sulphate gradient is 
ideal for drugs supplied as an HCl salt. (25) Like gemcitabine, these drugs form an 
equilibrium existing either in their water soluble salt form or uncharged as a free base. This 
equilibrium is a function of their pKa value, which is expressed by equation 4: 
 
 
 Equation 4: BH+ + Cl- ⇌ B + HCl 
 with B as the free base and BH+ as the cation of the salt form. 
 
 
Gemcitabine HCl has a pKa of 3.58. (28) According to the Henderson-Hasselbalch equation, 
the amount of salt form equals the amount of basic form when pH equals pKa (equation 5). 
 
 







A solution of 38 mg/ml gemcitabine has a theoretical pH of 2.2 and is protonated to 95.7 %. 
However, Gemzar contains NaOH and HCl for pH adjustment, which leads to a higher pH 
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ranging from 2.7 to 3.2 after preparation. (29) The pH of reconstituted Gemzar was measured 
to be 2.9. Accounting for the dilution with incubation, the pH of the outer phase was 
calculated to 4.85 for the sample loaded with 60 µl of dFdC HCl. At this pH, 94.9 % of 
gemcitabine is unprotonated and therefore able to penetrate the liposome membranes. Once 
inside the liposomes, the acidic environment with pH ~2.7 (25) leads to a 85.7 % protonation 
of the gemcitabine base, resulting in the entrapment. 
 
Reconstituted Gemzar was added to the liposome dispersion after the gradient was considered 
satisfactory. After varying incubation conditions, free dFdC were separated from the 
encapsulated dFdC on an ion exchange column (see section 5.5.5.2) before the EE of dFdC 
was determined by high performance liquid chromatography (HPLC). 
 
5.4.6 Passive loading of dFdC into VPG 
Passive loading of gemcitabine into VPG was carried out according to Moog et al as follows: 
• 500.0 μl of dFdC solution was transferred into a second vial already containing 3.71 g 
of VPG and 6.0 g of glass beads. The closed vial was centrifuged for 10 minutes at 
1500 rpm before incubation for one hour at room temperature. 
• The vial was centrifuged for another 5 minutes at 1500 rpm before incubation at 60 ˚C 
in a heater for two hours. 
• The VPG was diluted with 6.4 ml 9 mg/ml NaCl solution immediately before the 
cation exchange chromatography was executed.  
 
5.5 Analytical methods 
5.5.1 Photon Correlation Spectroscopy – PCS 
Theory: 
PCS is an analytical tool to determine the size distribution of particles. The method is based 
on dynamic light scattering, where a laser light beam is sent through the sample of interest. 
The particles in the sample scatter the laser light depending on their MW, size and shape. (30) 
 
Individual scattered waves from individual particles will interfere. The particles move in 
random Brownian motion and therefore, the scattered wave, or intensity at the detector site, 
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will fluctuate with time. (30) The scattered wave arriving at the detector site has a phase 
relationship dependent on the incident laser wave and the particles precise position. (30) 
Small particles will diffuse more rapidly compared to large particles and consequently give a 
more rapidly fluctuating intensity signal. (30) In contrast large particles are characterised by a 
signal with slowly fluctuating intensity. (30) 
 
The temperature must be constant in order to reduce the influence of thermal convection on 
the intensity fluctuations. The fluctuating wave scattering signal detected at the beam 
determines the diffusion coefficient of the particles and the particle radius can be calculated 
utilising the Stokes-Einstein equation. (30) 
 
Fitting and interpretation of the results: 
The software is able to evaluate data according to two different distribution-models fitted to 
the particle size distribution of the sample. The Gaussian distribution is the simplest approach 
in determining particle size and is restricted to normal distributions. For other distributions the 
more advanced NICOMP model is well suited since it assumes polydisperse samples. (18) 
 
The Gaussian model states how well a fit is approaching a normal distribution. The quality of 
this fit is given by Chi squared (χ2). A good fit requires a value between one and two whereas 
a value equal to or below one indicates an exceptionally good fit. On the contrary, a value 
above three represents poor fit and it is recommended to change to NICOMP distribution. A 
second parameter called Baseline Adjust reveals the presence of aggregates and other 
contaminants such as dust particles, which is considered negligible when measured close to 
zero. (18) 
 
For the NICOMP model the fit error addresses the stability of the results, with recommended 
values below 1.5 and preferably close to 1.0 in order to achieve reproducible and accurate 
results. Residual is a parameter indicating the presence of measured aggregates or other 
contaminants and for negligible amounts, the value should be 0.0. Significant amounts of 
contaminants are present at a value of 10 or larger. (18)  
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Experiment: 
Measurements were carried out as described by Ingebrigtsen and Brandl. (31) This quality 
control method was employed to determine the average size of liposomes. In brief, 50 g/L 
glucose, filtrated through a bottle top 0.22 μm filter, was used as a medium for diluting the 
liposome samples. The test tubes were placed in an ultrasonic bath for 15 minutes and then 
rinsed with the medium solution in a LAF bench in order to reduce particle contamination. 
The samples were diluted with freshly filtrated medium within the LAF bench until reaching 
an intensity level of 250–350 kHz as stated in the Nicomp user manual. (30) 
 
Before measurements were performed the instrument parameters were set according to correct 
values as listed in Table 7. 
 
 





Liquid index of refraction – 50 g/L glucose 1.3402 (32) 
Intensity set point 300 
Channel width Auto set 
 
 
Three cycles of 5 to 15 minutes were run for each sample in order to achieve readings in 
triplicates of the mean size with a value of collected data above 1000K (1 million) in order to 
ensure high statistical accuracy. (33) 
 
5.5.2 Quantification of ammonium sulphate by conductivity measurements 
A conductivity meter was used for determining unknown concentrations of ionic solutions 
based on a standard curve. The conductivity of free ammonium sulphate can be measured 
whereas the encapsulated ammonium sulphate is expected to have a conductivity of zero since 
the liposome membranes act as insulators. For conductivity measurements and determination 
GEMCITABINE CONTAINING LIPOSOMES 
MATERIALS AND METHODS 
 
HILDE GRAVEM 2006  
36 
of the ammonium sulphate EE, liposomes were destroyed in order to free the encapsulated 
ammonium sulphate. 
 
Standard curves were prepared in order to determine the concentration of ammonium sulphate 
within and outside liposomes. 
 
5.5.2.1 Ammonium sulphate in 50 g/L glucose solution 
A standard curve was prepared for ammonium sulphate in 50 g/L glucose solution. The 
conductivity of known concentrations of ammonium sulphate was measured. This resulted in 
a standard curve used for determining the unknown concentrations of ammonium sulphate. 
Approximately the same concentrations were used as in the experiments of Haran et al (24) 
ranging from 0.016 mM to 120 mM of ammonium sulphate and measurements were executed 
at 4.0 ˚C. Preliminary tests showed that measurements at 4.0 ˚C were challenging to comply 
with, therefore all solutions and equipments were cooled down in an ice bath until reaching 
temperature of about 0.5 ˚C. Measurements were performed at temperatures ranging from 0.3 




Table 8: Conductivity measurements for the standard curve – ammonium sulphate in 50g/L glucose 
 
Parallel 1 Parallel 2 Parallel 3 (NH4)2SO4 
(mM) in 










120 11300.0 0.5 11400.0 0.4 11400.0 0.4 57.7 
80 8020.0 0.4 8030.0 0.6 7960.0 0.5 37.9 
60 6140.0 0.3 6120.0 0.4 6150.0 0.5 15.3 
24 2730.0 0.5 2740.0 0.5 2730.0 0.5 5.8 
12 1454.0 0.6 1453.0 0.5 1453.0 0.6 0.6 
1.2 164.8 0.5 164.9 0.5 164.7 0.4 0.1 
0.12 18.0 0.5 18.0 0.5 18.0 0.5 0.0 
0.012 2.7 0.5 2.8 0.5 2.8 0.5 0.1 
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Conductivity of ammonium sulphate in 50 g/L 
glucose
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5.5.3 Determination of ammonium sulphate entrapment 
The liposomes entrapping ammonium sulphate were separated from non-entrapped 
ammonium sulphate. The liposome fraction was collected and its conductivity measured in 
order to calculate the remaining external amount of ammonium sulphate. Various attempts 
were made to destroy the liposomes (see section 6.4). The final approach was as follows: A 
sample of the liposome fraction was diluted with dialysed 10 % triton solution (in a ratio of 
1:1) to annihilate the liposomes and measure the conductivity for calculating the amount of 
ammonium sulphate within the whole solution. Using these two values the amount of 
ammonium sulphate inside the liposomes was determined. 
 
5.5.4 Quantification of gemcitabine through Reversed-Phase High Performance Liquid 
Chromatography – RP-HPLC 
Gemcitabine was quantified using RP-HPLC, according to a method developed by Håkonsen. 
(34) Briefly, a calibration curve of gemcitabine was prepared through HPLC in order to 
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The sample solution is injected into a mobile phase, which acts as a carrier for the sample. 
The mobile phase then flows through the stationary phase within the column. Components of 
the sample begin migrating through the column at the same time. However, they will travel at 
a speed, and separate, depending on interactions with the stationary phase. A reverse 
stationary column (C8) is used in these experiments to separate gemcitabine from lipids, triton 
solution and glucose. The stationary phase is non-polar whereas the mobile phase is polar. 
Samples with strong interactions with the stationary phase will stay on the column for a 
longer time compared to weaker interactions and consequently result in longer retention time 
and vice versa. An isocratic method is used in these experiments. The detector signals the 
resultant peak(s) seen in the chromatogram. (35) 
 
A series of known concentrations of gemcitabine was injected into the HPLC resulting in 
peaks correlating to the concentrations. A calibration curve was developed, by plotting the 
area under the curve (AUC) from the peaks versus the concentration of the samples. Using 
this calibration curve, quantification of unknown gemcitabine could be executed. (36) 
 
Experiment: 
All HPLC eluants were filtrated using either a Millipore Nitrocellulose filter with 0.1 µm pore 
size or Sartorius polyamide filter with 0.22 µm before usage, reducing the possibility of 
precipitation blocking the column. The column was stored in acetonitril and had to be washed 
thoroughly with distilled water before changing to the mobile phase, phosphate-methanol 
buffer, in order to prevent salt precipitation. The parameters were set according to Moog et al 
and are listed in Table 9. 
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Table 9: HPLC parameters used for quantification of gemcitabine 
 
Injection volume 50 μl 
Mobile phase 25 mM phosphate buffer (pH 6.9)/methanol 92.5:7.5 
Flow rate 1 ml/min 
UV detection wavelength  278 nm 
Column temperature 40˚C 
column LiChrospher 60, RP- Select B (5 µm) 250mm x 4 mm 
Packing material of column C-8 
 
 
The standard curve was obtained from triplicates of each sample with concentration ranging 
from 50 ng/ml to 5400 ng/ml. (34) As seen from Figure 9, the calibration curve reveals a good 





Figure 9: Standard curve used for quantification of dFdC 
 
 
Standard curve of gemcitabine












0 1000 2000 3000 4000 5000 6000





GEMCITABINE CONTAINING LIPOSOMES 
MATERIALS AND METHODS 
 
HILDE GRAVEM 2006  
40 
A typical chromatogram of a sample of gemcitabine is shown in Figure 10. This 




Figure 10: A typical chromatogram of gemcitabine 
 
 
5.5.5 Determination of encapsulation efficiency of gemcitabine 
External gemcitabine must be separated from encapsulated gemcitabine before dissolving the 
liposomes in order to determine the EE. This separation was performed using a cation 
exchange column. (13) In order to quantify the amount of dFdC, and determine the EE, two 
samples from the same loaded sample set were compared. One sample was separated through 
the cation exchange column removing the external dFdC whereas the second sample, used as 
a reference, was not. Samples containing encapsulated and free dFdC and samples containing 
only encapsulated dFdC were quantified according to section 5.5.4. The column was prepared 
and set out according to Moog as follows: (15) 
5.5.5.1 Preparation of the Lichrolut cation exchange column: 
• PTFE-frits were placed within the column. 
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• The column was filled with excess distilled water followed by stirring for removal of 
air bubbles. 
• After 5 minutes, when sedimentation has completed, excess water was removed by 
vacuum until the cationic exchanger was just covered with water. 
 
The column was loaded with saturated NaCl solution before it was flushed with distilled 
water followed by drying under vacuum conditions. The setup of Lichrolut cation exchange 





Picture 2: Setup of cation exchange columns 
 
 
5.5.5.2 Cation exchange separation: 
0.5 ml of loaded liposome samples was added drop wise to the column followed by 10 
seconds of suction. The column was then eluted with 0.5 ml distilled water every 10 seconds, 
repeated four times, while the liquid was collected under continuous suction.  
 
The eluate for the gemcitabine determination was collected in a 10.0 ml volumetric flask and 
diluted with 10 % triton solution up to 10.0 ml. 2.5 ml of the diluted sample was then further 
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diluted with 10 % triton solution in a 25 ml volumetric flask before its final dilution of 1:2 
with 25 mM phosphate buffer. Gemcitabine was then quantified via HPLC.  
 
As a reference, containing external and encapsulated dFdC, 125 μl unseparated sample, from 
the same sample set as used above, was diluted with 10 % triton solution in a 25 ml 
volumetric flask. Finally, it was diluted with phosphate buffer in the same manner as for the 
sample separated through the ion exchange column. The reference was then ready for 
injection into the HPLC.  
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6 RESULTS AND DISCUSSION 
6.1 Preliminary experiments 
6.1.1 Preparation of ammonium sulphate-containing liposomes of defined size 
Lipsomes were prepared by the hand shaken method according to section 5.4.1.1 and by the 
film method according to section 5.4.1.2. Extrusions were carried out following the methods 
described under hand driven filter extrusion and continuous high pressure filter extrusion. 
 
The liposomes mean diameter was measured using PCS. For calculating sizes, the software 
requires the refractive index of the dispersion medium. The refractive index of 5% glucose 
solution was initially not known, so calculations were done using the refractive indices for 10 
% glucose and for water, respectively. The results showed a small variation in the mean 
liposome size (data not shown). Later on, the refractive index for 5 % glucose was found in 
literature (32) and used for further PCS analysis. Table 10 shows a typical result for the mean 
liposome sizes of liposomes prepared by the hand shaken method and filter extruded using the 
continuous high pressure extruder. 
 
 
Table 10: Example of results from PCS analysis 
 
Measurement 1: mean vesicle size ± SD  115.4 ± 45.4 
Measurement 2: mean vesicle size ± SD  107.7 ± 44.6 
Measurement 3: mean vesicle size ± SD  114.0 ± 45.1 
Mean of parallels: mean vesicle size ± SD  112.4 ± 45.0 
Measurement time (min) 15 
Collected data in channel no 1 >1000 K 
 
 
The liposomes show a slightly larger mean diameter than the filter pore size used for 
extrusions. This can be explained by the flexibility of the liposomal membranes leading to 
alterations in shape while squeezing through the filter pores.  
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According to Frantzen dispersions displaying Gaussian distributions, should preferably 
display standard deviations (SD) below 15 percent. (33) As seen from Table 10, the average 
SD was approximately 45 %. This high percentage indicates a wide Gaussian size 
distribution, (33) i.e. the presence of liposomes of different sizes.  
 
6.1.2 Reduced conductivity of liposome dispersions 
When the ammonium sulphate solution, with a conductivity of approximately 11.3 mS/cm, 
was mixed with E-80 the conductivity of the resultant liposome dispersion was substantially 
decreased. The measured conductivity of the liposome dispersions varied between 7.69 and 
8.5 mS/cm depending on the batch measured. A possible explanation for this phenomenon is 
that entrapped ammonium sulphate is not contributing to the overall conductivity since the 
liposomes act as insulators. In this way only the ammonium sulphate in the outer aqueous 
phase will display conductivity. This is supported by Lidgate, Hegde and Maskiewicz, who 
discovered a reduced conductivity upon formation of liposome dispersions as compared to the 
conductivity of the hydrating buffer alone. (38) The reduction in conductivity was shown to 
be dependent on lipid concentration, the buffer ionic strength and the liposome size. They 
found the net loss of conductivity to be a convenient measure of the captured volume in 
liposomes. (38) By using the loss in conductivity as a measure for captured volume, 
approximately 70 % of the ammonium sulphate in this experiment was in the outer aqueous 
phase, whereas approximately 30 % were most likely encapsulated within the liposomes. 
 
6.1.3 Removal of non-entrapped ammonium sulphate from the liposomes 
Size exclusion chromatography was chosen as a method to separate the liposomes from non-
entrapped ammonium sulphate. A series of separation attempts was carried out in order to 
determine the most appropriate application volume to the column for achieving the greatest 
separation. Tested volumes varied from 1.0 ml to 10.0 ml and their resultant conductivities are 
listed in Table 11.  
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E-80 10.0  32.0 1060.0 
E-80 5.0  25.0 572.0 
E-80/CH 5.0 35.0 37.1 
E-80/CH 1.0  16.5 6.8 
 
 
The conductivity of the surrounding medium of the liposome fraction was measured in order 
to check if the ammonium sulphate outside the liposomes was removed successfully. A 
conductivity of approximately 7 to 1000 μS/cm was measured at 0.5 ˚C as compared to about 
8 mS/cm in the liposome dispersion before fractionation. The difference in conductivity 
indicates that the external ammonium sulphate was widely removed during gel 
chromatography. But, significant differences were observed between the different sample 
volumes. In general, the removal of ammonium sulphate was more complete with lower 
application volumes. 
 
A distinct optimum seemed to be reached with an application volume of 5.0 ml. Although the 
conductivity decreased even more with smaller volumes the column diluted the samples to 
such a great extent, making the results less reliable due to low signal to noise ratios. 5.0 ml 
seemed to be the most satisfactory application volume and was therefore used in subsequent 
experiments.  
 
The volumes and duration taken for collecting the different fractions, of a 5 ml application 
volume, are listed below in Table 12. 
 
 
Table 12: Fractions from separating a 5.0 ml sample through the gel column 
 
Fraction Volume (ml) Duration (s) 
void fraction 20.0  155 
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Liposome fraction 26.4  159 
 
6.1.3.1 Fluctuating conductivity 
The conductivity of free ammonium sulphate was measured numerous times within the same 
batch and between different batches. However, the conductivity was varying to a greater 
extent than the differences in volume of the liposome fractions could account for. In addition, 
the size of the conductivity indicates the presence of free ammonium sulphate to a larger 
extent than considered optimal. This can be due to two reasons, firstly, the possible outcome 
of unsatisfactory separation through the column. Attempts were made in finding a suitable 
volume of liposome dispersion added to the gel column in order to give a satisfactory amount 
of free ammonium sulphate in the liposome fraction. Secondly, the measured conductivity of 
non-encapsulated ammonium sulphate may have been increased by ammonium sulphate 
leaking through the lipid membrane. It is generally accepted that liposomes prepared from 
natural, fluid egg PC, like E-80, do not form as tightly packed bilayers as liposomes 
containing cholesterol.  
 
Attempts in reducing contaminating effects on the results: 
• Sephadex matrix was replaced every 1-2 months. 
• The conductivity meter was washed thoroughly with 96 % ethanol and 5 % glucose 
before measurements in order to eliminate a possible liposome film on the 
conductivity meter.  
• Liposomes were freshly prepared every three weeks (liposomes composed of only E-
80 showed to degrade due to discolouration). 
• The gel column was rinsed thoroughly with 50 g/L glucose in order to flush through 
any residual ammonium sulphate ions from the previous separation. This was done 
experimentally by measuring the conductivity of fractions of the washing solution and 
a volume of 500 ml was considered appropriate in order to eliminate residual 
ammonium sulphate ions. This can be seen from Table 13. 
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Conc of (NH4)2SO4 
(mM) 
Void volume 9.0 22.0 N/A 
Liposome fraction 572.0 25.0 2.07 
Combined fraction just before 




3 2562.0 10.0 9.50 
4 1793.0 20.0 16.86 
5 175.9 20.0 0.60 
6 9.0 300.0 N/A 
7 7.0 20.0 N/A 
*) Value in brackets is the original volume of the fraction. The conductivity is based on the total volume, which 
is adjusted for in the concentration. 
 
 
6.1.4 Qualitative proof for active loading 
In order to check whether an ammonium sulphate gradient was established after the removal 
of external ammonium sulphate removal in the liposome fraction, liposomes were incubated 
with saturated acridine orange solution for 10 and 30 minutes, respectively. The loaded 
liposomes were separated from free acridine orange by SEC in the same manner as for the 
separation of external ammonium sulphate. 
 
The collected fractions from the two different incubation conditions with acridine orange 
during separation are listed in Table 14. 
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Table 14: Separation results after acridine orange loading 
 
10 minutes incubation 30 minutes incubation Fraction 
Volume (ml) Time (s) Volume (ml) Time (s) 
50 g/L glucose (void) 16.5 155 17.6 160 
Liposome fraction 22.0 110 23.0 140 
50 g/L glucose (fraction in 
between) 
14.2 65 13.0 60 
Free acridine orange 
fraction (excess) 
22.4 120 28.0 130 
 
 
A yellowish liposome fraction would indicate successful loading of acridine orange into 
liposomes. The visual results indicated successful loading of acridine orange both after 10 
minutes and 30 minutes incubation as it can be seen from Picture 3. The orange band in the 
middle contains the fraction of liposomes loaded with acridine orange, whereas the free 
acridine orange is still within the top part of the column. 
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Picture 3: SEC of liposomes loaded with acridine orange 
 
 
6.2 Stability of ammonium sulphate solution during heating 
Since dissolving liposomes may require heating of the dispersion0, it was first examined, 
whether ammonium sulphate was stable at elevated temperatures. Since ammonia is known to 
evaporate easily and the concentration of ammonium sulphate is directly related to 
conductivity, the conductivity upon incubation at different temperatures was measured. 
 
The standard curve, ranging from 0.12 mM to 120 mM (see section 5.5.2.1), was used as a 
reference in determining the concentration of ammonium sulphate. The conductivity of 
freshly prepared 120 mM ammonium sulphate solution was measured at 0.5 ˚C yielding a 
conductivity value of approximately 12 mS/cm. To discover the effect of different 
temperatures on ammonium sulphate, the conductivity of ammonium sulphate solutions was 
measured at different temperatures over time. This was performed in glass bottles without lids 
at 0.5 ˚C as well as at 60 ˚C. The solution incubated in an ice bath at 0.5 ˚C for 40 minutes 
had a conductivity of 12 mS/cm. The solution incubated at to 60 ˚C for 40 minutes (and 
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cooled down to 0.5 ˚C) showed a conductivity of 11.7 mS/cm, hence a small reduction in 
concentration upon air and temperature exposure. 
 
6.3 Standard curve for quantification of remaining non-entrapped 
ammonium sulphate in the liposome fraction 
The standard curve of ammonium sulphate in 50g/L glucose, described in section 5.5.2.1, was 
found not to be fully adequate for quantification of remaining non-entrapped ammonium 
sulphate due to low conductivity of some of the diluted samples. These samples had 
conductivities below 181.59 μS/cm.  
 
The dilution factor typically occurring in the liposome fraction was derived from the 
experiments and a new standard curve with a more appropriate concentration range was made. 
The dilution steps gave rise to a dilution factor of 70 giving a theoretical maximum 
concentration of ammonium sulphate of 1.714 mM. A maximum concentration of 5 mM was 
included as the highest concentration in the standard curve by including some tolerance. 
Furthermore, this standard curve was obtained at a temperature of 30 ˚C. This was done 
because of problems in dissolving liposomes at 0.5 ˚C and since ammonium sulphate showed 
to be stable under the applied heat treatment. It required less time to heat samples up to 30 ˚C 
compared to cooling them down to 0.5 ˚C and the temperature could be easier adjusted to 
exactly 30 ˚C compared to 0.5 ˚C. 
 
The conductivity measurements are listed in Table 15 and Figure 11 shows the standard 
curve. 
 
GEMCITABINE CONTAINING LIPOSOMES 
RESULTS AND DISCUSSION 
 
HILDE GRAVEM 2006  
51 
Table 15: Conductivity measurements for standard curve of ammonium sulphate in 50 g/L glucose 
 
Conc (mM) of 











SD of triplicate 
 
5.0 1337.0 1340.0 1341.0 2.1 
2.5 696.0 698.0 6970.0 1.0 
1.25 360.0 361.0 361.0 0.6 
0.625 186.9 187.4 187.5 0.3 
0.3125 97.7 97.3 97.1 0.3 
 
 
Standard curve of ammonium sulphate in 50 g/L 
glucose
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Figure 11: Standard curve for ammonium sulphate in 50 g/L glucose solution 
 
 
This standard curve of ammonium sulphate in 50 g/L glucose solution revealed a good linear 
fit with a R2 value of 0.9997. 
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6.4 Quantification of entrapped ammonium sulphate 
The amount of entrapped ammonium sulphate in liposomes should be determined in order to 
control the encapsulation process and to evaluate the magnitude of the established 
transmembrane gradient. This was executed by dissolving the liposomes of the liposome 
fraction (upon gel fractionation) and measuring the conductivity of the resulting diluted 
solution. 
 
Various attempts were tried for dissolving the liposomes in order to determine the ammonium 
sulphate concentration by conductivity measurement. In order to eliminate the possibility of 
influences on the results by dissolved E-80 and the dissolving agent, all components used in 
experiments were also included in this standard curve for dissolved liposomes. Thus each 
attempt required a new standard curve.  
 
6.4.1 Standard curve for quantification of entrapped ammonium sulphate in the 
liposome fraction upon disintegration with ethanol 
Attempts were made to dissolve liposomes by addition of ethanol and heating of the sample 
up to 30 ˚C. Initially, one part of the liposome fraction was dissolved in nine parts of 96 % 
ethanol giving a ratio of 1:10. The disappearance of turbidity indicated that the liposomes 
were dissolved. Then, a standard curve was established, where the composition of the 
standards was identical to those of the samples i.e. in accordance to the dilution factors. This 
was achieved during preliminary experiments as follows: 
 
142.86 mg E-80 dissolved in 
90.0 ml of 96 % ethanol and 
10.0 ml ammonium sulphate in 50 g/L glucose solution in concentrations as lined out below 
in Table 16. 
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Table 16: Conductivity measurements of entrapped ammonium sulphate in the liposome fraction 
dissolved by ethanol 
 
Conc (mM) 










SD of triplicate 
3 88.7 88.7 88.7 0.0 
2 79.4 79.3 79.2 0.1 
1 49.1 49.1 49.1 0.0 
0.5 32.1 32.0 32.1 0.1 
0.25 22.3 22.4 22.3 0.1 
0.125 16.3 16.3 16.3 0 
0.0625 13.3 13.3 13.3 0 
 
 
The solution containing 3 mM ammonium sulphate turned out to be turbid at 30 ºC indicating 
precipitation, most probably of ammonium sulphate. Although the less concentrated standard 
solutions appeared clear, a small amount of particles was visible upon close inspection. The 
appearance of these particles led to an uncertainness whether it was dust particles or 
precipitating ammonium sulphate. 
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Standard curve for quantification of entrapped 
ammonium sulphate









0 0,5 1 1,5 2 2,5 3 3,5












Figure 12: Standard curve for liposomes dissolved with ethanol 
 
 
The graph in Figure 12 demonstrates a poor linear fit most likely due to precipitation of 
ammonium sulphate. The conductivity does not appear to increase linearly with increasing 
ammonium sulphate concentrations. This is contrary to what is expected and thus responsible 
for the poor linear fit. Furthermore, the fitted line of the standard curve would cross the y-axis 
at approximately 16 μS/cm instead of going through the zero-point. This observation also 
confirms a deviation from a linear fit. This means utilising this standard curve would give rise 
to misleading concentrations in the whole range, from very small concentrations to very large 
concentrations. 
 
In the same manner, two new standard curves were executed with a decreased amount of 
ethanol. Instead of a liposome fraction: ethanol ratio of 1:10 the solutions had ratios of 1:7 
and 1:5 (results not shown). The results were comparable to the above findings with the ratio 
of 1:10 with 96 % ethanol, i.e. the occurrence of ammonium sulphate precipitation. For this 
reason 96 % ethanol was ruled out as a suitable agent for disintegration of liposomes. 
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6.4.2 Quantification of entrapped ammonium sulphate in the liposome fraction upon 
disintegration with triton solution 
In the next attempt Triton X-100 was used instead of 96 % ethanol. Triton or 2-methyl-1,3,5-
trinitro-benzene is a non-ionic detergent. The liposome fraction was initially dissolved by 
addition of a 10 % triton solution in a 20:1 ratio. Cholesterol containing liposomes underwent 
a temperature treatment of 80 ˚C to facilitate disintegration whereas liposomes composed of 
only E-80 were dissolved at room temperature.  
 
To check whether triton solution had an influence on the measured conductivity of the 
fraction containing the destroyed liposomes, the conductivity of the 10 % triton solution alone 
was measured. The solution of 10 % triton revealed a conductivity of 48 μS/cm at 0.5 ˚C. This 
means the conductivity of the triton solution was unexpectedly high, in fact in the same 
magnitude as the conductivity of ammonium sulphate from the liposome fraction. 
 
In order to reduce the contribution of the triton solution to the overall conductivity, smaller 
amounts were tried for dissolving the liposomes. The liposome fraction, containing liposomes 
composed of E-80 and cholesterol, was therefore mixed with different amounts of triton 
solution: 
 
1:20 1 ml liposome fraction and 19 ml 10 % triton solution 
1:10 2 ml liposome fraction and 18 ml 10 % triton solution 
1:5 4 ml liposome fraction and 16 ml 10 % triton solution 
1:1 10 ml liposome fraction and 10 ml 10 % triton solution 
 
As a reference, solutions of 50 g/L glucose with the same fractions of triton solution were 
prepared. In this way variations in the conductivity of the broken liposomes could be 
identified and thus a suitable amount of triton solution detected. 
 
1:20 1 ml 5% glucose and 19 ml 10 % triton solution 
1:10 2 ml 5% glucose and 18 ml 10 % triton solution 
1:5 4 ml 5% glucose and 16 ml 10 % triton solution 
1:1 10 ml 5% glucose and 10 ml 10 % triton solution 
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All solutions were preheated to 80 ˚C for 30 minutes before measurements and all solutions 
appeared to be clear when measured, which indicated disintegration of the liposomes. The 
results of conductivity measurements are listed in Table 17. 
 
 
Table 17: Disintegration test. Disintegration of liposome fraction in various amounts of triton solution 
 
Conductivity μS/cm  
1:20 1:10 1:5 1:1 
Liposome fraction + triton solution 53.5 56.8 58.2 86.3 
Reference (50 g/L glucose + triton solution) 47.1 45.1 41.6 28.5 
Liposome fraction – reference (pr ml) 6.40 5.85 4.15 5.78 
 
 
The contribution of the triton solution to the overall conductivity was regarded as 
unacceptable for all the investigated mixing ratios. 
 
The conductivity of triton solution from different batches and producers may vary due to the 
presence of salt residues from production. In addition, the 10 % triton solution (with a 
conductivity of 108 μS/cm at 30 ˚C) used for the experiments was produced in house one year 
ago and could have been suspect for contamination over the past year. Therefore, new 10 % 
solutions were prepared and their conductivity measured. Triton X-100 from Sigma and 
Merck was used in the solutions giving conductivities of 410 μS/cm and 140 μS/cm, 
respectively. Triton X-100 should display the same conductivity regardless of the choice of 
manufacturer. However, the presence of salt residues leading to variations in conductivity of 
the raw material has shown to be evident. Therefore, as a result of these findings, it was 
decided to undertake dialysis of triton solution. 
 
6.4.2.1 Dialysis treatment of triton solution 
A dialysis treatment of the 10 % triton solution was conducted trying to reduce its 
conductivity by removing any possible salt residues. To maximise the dialysis effect a dialysis 
bag containing 20 ml of 10 % triton solution was placed in two litres of distilled water 
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overnight in order to generate a sink being 100 fold greater than the sample solution. This can 





Picture 4: Dialysis treatment of 10 % triton solution 
 
 
The dialysis treatment turned out to have a large impact on the measured conductivity of the 
10 % triton solution. The conductivity was reduced to 4 μS/cm. However, the concentration of 
the solution is also influenced by dialysis, becoming slightly lower due to water molecules 
diffusing into the solution through the semipermeable membrane. This did not impose a 
problem for the experiments since 10 % triton solution was used for destruction of liposomes 
in excess amounts, and its exact concentration had no relevance.  
 
6.4.2.2 Standard curve for quantification of entrapped ammonium sulphate in the liposome 
fraction upon disintegration with dialysed triton solution 
The liposome fraction was dissolved with dialysed triton solution giving a ratio of 1:1. At this 
point, only liposomes containing E-80 were used for experiments and therefore a dilution 
factor of 1:1 seemed sufficient in order to dissolve the liposomes. The composition of the 
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samples for the standard curve was determined in the same manner as for the samples 
containing ethanol.  
 
Accounting for the dilution step by the cation exchange column (1:7), the total dilution factor 
was 1:14. The conductivity measurements are given in Table 18 whereas the standard curve is 
illustrated in Figure 13. 
 
 
Table 18: Conductivity measurements of entrapped ammonium sulphate in the liposome fraction 
dissolved by triton solution 
 











SD of triplicate 
10  2550.0 2550.0 2510.0 23.1 
7.5  1970.0 1940.0 1960.0 15.3 
5 1340.0 1330.0 1350.0 10.0 
2.5 741.0 740.0 742.0 0.6 
1.25 418.0 419.0 419.0 0.6 
0.625 254.0 253.0 251.0 1.5 
0.3125 167.0 167.0 166.0 0.6 
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Standard curve for quantification of entrapped 
ammonium sulphate 









0 2 4 6 8 10 12












Figure 13: Standard curve for quantification of entrapped ammonium sulphate in liposomes. Dissolved 
with triton solution 
 
 
The standard curve displays a good linear fit with a R2 value of 0.9996. This implies the 
absence of ammonium sulphate precipitation by using 10 % triton solution in dissolving 
liposomes. The detergent has proved to be successful in dissolving the liposomes with 
minimal influence on the conductivity.  
 
6.5 Method validation of quantification of ammonium sulphate inside the 
liposomes 
Upon establishment of an appropriate disintegration method the quantification of ammonium 
sulphate within the liposomes could be determined. After various attempts, the development 
of a method was completed. 
 
6.5.1 Determination of the recovery 
In order to get reliable results, the recovery of the SEC should be close to 100 %. 5.0 ml 
liposome dispersion, containing 600 µmol ammonium sulphate, was added to the gel column. 
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By collecting all fractions from the gel column the recovery of the originally 600 μmol 
ammonium sulphate was determined (Table 19). 
 
 












Void volume 9.0 22.0 N/A N/A 
Liposome fraction 572.0 25.0 2.07 51.8  
Dissolved liposome 
fraction 
650.0 25.0 (50.0) 2.37 (4.74) 118.5 
Combined fraction 
just prior and after 
liposome fraction 
394.0 20.0 (6.5)* 4.3 28.0 
3 2562.0 10.0 9.5 95.0 
4 1793.0 20.0 16.9 337.2 
5 175.9 20.0 0.6 12.0 
6 9.0 300.0 N/A N/A 
7 7.0 20.0 N/A N/A 
Σ (NH4)2SO4 in all fractions (mg) 591 
Values in brackets are adjusted for dilution steps. 
 
 
A total amount of 591 μmol ammonium sulphate was recovered from the various fractions 
from the column as seen from the table. This corresponds to a recovery of 98.4 %. The high 
recovery, together with the reproducible and reasonable encapsulated amount of ammonium 
sulphate of the liposome fraction, was considered satisfactory and thus accepted as constants 
throughout the experiments. 
 
6.5.2 Quantification of entrapped ammonium sulphate 
The amount of substance of entrapped ammonium sulphate was established from the 
conductivity and thus concentration of the dissolved and the undissolved liposome fraction. 
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The difference of the amounts of substance between the undissolved liposome fraction and the 
dissolved liposome fraction gave an amount of 66.8 μmol. This amount represents the amount 
of substance of entrapped ammonium sulphate. The gradient was determined by dividing the 
concentration of external ammonium sulphate in the liposome fraction with the concentration 
of encapsulated ammonium sulphate. This yielded a gradient of about 1:58.  
 
A gradient of 1:58 is quite small with respect to gradients published in the literature. Haran et 
al. achieved a 1000 fold gradient, however, by using other lipids. (24) Liposomes composed 
of E-80 are expected to result in phospholipid membranes not as densely packed compared to 
membranes containing cholesterol. Therefore, upon establishment of the gradient, ammonium 
sulphate may start to diffuse through the membrane according to its low tightness. This may 
be one explanation for the small gradient of ammonium sulphate between the outer and inner 
phase of E-80 composed liposomes. In order to reduce the magnitude of the leakage through 
the membrane, SEC, loading and cationic exchange was performed on the same day. Another 
possible explanation for the small gradient is the relatively high remaining ammonium 
sulphate concentration in the external medium of the liposome fraction upon size exclusion 
chromatography. As demonstrated in table 10 a further reduction in remaining ammonium 
sulphate in the external medium of the liposome fraction would probably be achieved by 
further reducing the sample volume applied to the column.  
 
Comparing the absolute amount of entrapped ammonium sulphate to the absolute amount of 
total ammonium sulphate retained from the column gave an EE of 11.30 %. An EE of the 
magnitude of 11.30 % seems reasonable considering the mean size and lipid concentration of 
the liposome dispersion. 
 
It is widely recognised that EE decrease with decreasing liposome size (4, 27) and decreasing 
lipid concentration. (37, 38) Berger et al found that liposomes with size ranging from 400 nm 
to 50 nm, led to an EE varying from approximately 40 % to 10 %, respectively. (37) 
Liposome size of 100 nm, as used in these experiments, had an EE of approximately 15 %. 
However, 15 % lipid concentration was used in the research of Berger et al. (37) Only 10 % 
lipid concentration was used in these experiments and could therefore explain the slightly 
deviating EE.  
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6.5.3 Entrapped volume of liposomes 
From the EE the actually entrapped volume of the 5.0 ml fraction can be determined. This 
gave an encapsulated volume within the liposomes of 0.565 ml. 
 
The encapsulated volume of 0.565 ml deviates greatly from the theoretically encapsulated 
volume of 1.5 ml (out of 5.0 ml) derived from the 30 % EE obtained by conductivity 
differences in section 6.1.2. A plausible explanation for this variation could be the effect of 
liposome size. Lidgate, Hegde and Maskiewicz prove MLVs are associated with larger 
reductions in conductivity compared to SUV. (38) This means a smaller volume gets 
entrapped within SUVs compared to MLVs. Lidgate, Hegde and Maskiewicz found the 
captured volume could be calculated according to liposome size and amount of lipid present. 
(38) For MLVs the captured volume was 2.5 μl per mg lipid. This would give an EE of 25 % 
in these experiments. The captured volume for SUVs was 0.96 μl per mg lipid yielding an EE 
of 9.6 %. Giving this information, it could be expected the EE of 30 %, obtained by the 
reduced conductivity, was reflecting a liposome dispersion consisting of MLVs whereas the 
calculated EE of 11.30 % was reflecting a liposome dispersion consisting of SUVs. However, 
this is inexplicable since the conductivity measurements of the liposome dispersion were 
conducted after filter extrusions were carried out. 
 
The amount of substance of entrapped ammonium sulphate and the gradient was considered 
constant for all liposome fractions. Further, the amount of substance of entrapped ammonium 
sulphate is used for calculating active loading efficiencies.  
 
6.6 Loading of gemcitabine 
Both passive and active loading of dFdC into the interior aqueous compartment of liposomes 
was performed in order to compare the end results. The two methods have different variables 
such as lipid concentration and incubation conditions. However, the methods can be 
compared in the amount of encapsulated dFdC, EE and the ratio of dFdC: lipids.  
 
6.6.1 Passive loading 
The results from the HPLC determination of passively loaded dFdC are listed in Table 20. 
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Table 20: Detected concentrations of dFdC from passive loading 
 
Sample Conc run 1 (ng/ml) Conc run 2 (ng/ml) Mean conc of triplicate (ng/ml) 
T1 2701.9 2701.9 
T2 2913.4 2916.5 
T3 2768.8 2768.8 
2795.2 
E1 566.1 567.2 
E2 581.1 580.5 
E3 593.1 593.5 
580.3 
T = Total liposome dispersion (before removal of non-entrapped dFdC) 
E = Liposome dispersion after IEC-removal of non-entrapped dFdC 
 
 
The samples designed E had undergone cation exchange chromatography followed by 
disintegration and revealed the encapsulated amount of dFdC within the liposomes. The 
samples designed T did not undergo cation exchange chromatography and revealed the total 
amount of gemcitabine in the dispersion.  
 
6.6.1.1 Determination of amount of substance of dFdC 
The addition of 500 µl Gemzar solution containing 72.2 μmol dFdC to the VPG led to an 
average detected amount of 67.6 μmol in the fraction (equation 6), which correlates to a 
percentage recovery of 93.65 % (Sample T). 
 
 
 Equation 6: 
mol)g/(MW 
 (ml) V*600*g/ml)( dFdCmol)( dFdC totdetectedVtot μμ
μμ =  
(600 = dilution factor) 
 
 
6.6.1.2 Encapsulation Efficiency: 
For sample E the amount of substance of encapsulated dFdC was determined to be 14.0 μmol, 
according to equation 6. This gives an EE of 20.7 %. An EE of 20.7 % is smaller than 
previously published values. According to Moog et al, an EE of 33.2 ± 4.2 % was achieved 
for VPG produced of hydrogenated egg PC and cholesterol. (15) 
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Several effects might explain the lower EE. The difference in the liposome sizes between the 
VPG seems to play a major role. The homogenisation of the egg PC (E-80) lipid dispersion 
obviously leads to smaller particle sizes than homogenised hydrogenated egg PC/cholesterol-
liposomes described by Moog et al. Moog et al described that the VPG contained vesicles of 
60 to 80 nm in diameter, (15) while the largest fraction (79.6 - 99.1%) of the liposomes in our 
experiment had a smaller diameter of 21.5 to 37.9 nm. It is well recognised that a bigger 
aqueous core will result in a larger EE of hydrophilic compounds.  
 
The smaller EE might as well be explained by the composition of the liposomes that differs in 
the type of egg PC used and addition of cholesterol. The VPG prepared by Moog et al 
contained cholesterol which leads to tighter packed membranes and therefore a reduced 
leakage compared to lipid membranes composed of E-80 alone. A rapid leakage of dFdC 
during cation exchange separation might have affected the EE negatively in our case. 
 
6.6.1.3 Ratio of amount of encapsulated dFdC per amount of lipid 
The required amount of lipid per dFdC must be determined for receiving information about 
the quality of encapsulation.  
 
An amount of 14.0 μmol dFdC was encapsulated within the densely packed VPG. A 
concentration of 40 % E-80 with an average MW of 781g/mol (39) yields a theoretical 
amount of 1900 μmol PC in the sample of 3.71 g. Hence, 135.7 μmol of lipids are required in 
order to encapsulate one μmol of dFdC.  
 
6.6.2 Active loading 
Different incubation conditions for active loading of dFdC into E-80 liposomes were tried 
experimentally. Reconstituted Gemzar, containing 38 mg/ml dFdC, was used for the active 
loading experiments. 5.0 ml liposome fractions, from the gel column, were mixed with 
different amounts of dFdC solution. Upon completion of incubation, 0.5 ml of the sample was 
transferred to the ion exchange column in order to remove non-entrapped dFdC from outside 
the liposomes according to 5.5.5.2.  
 
GEMCITABINE CONTAINING LIPOSOMES 
RESULTS AND DISCUSSION 
 
HILDE GRAVEM 2006  
65 
The amount of encapsulated ammonium sulphate in the liposome fraction was experimentally 
determined only once as described in section 6.5.2 and was considered constant for all 
subsequent samples. But the slightly varying volumes of the liposome fractions upon SEC 
were taken into account and the amounts of dFdC added to the samples were adjusted 
accordingly. The results of active loading experiments at different incubation conditions are 
summarised in Table 21. 
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Table 21: Results from different incubation conditions of active loaded samples with dFdC 
 






EE (%) dFdCentrapped per 
(NH4)2SO4 encap (%) 
dFdC (mol):lipid 
(mol) 
A 3 h in RT 7.13 0.23 81.95 3.25 1.70 1:551.7 
C 2 h 45 min RT, 15 min 60 ̊ C 7.14 1.14 82.07 15.97 8.50 1:112.3 
F 48 h RT 7.18 1.20 87.56 16.71 9.50 1:100.0 
G 5 x ↑ conc, 24 h RT 35.08 4.52 85.77 12.88 35.89 1:26.6 
K 5 x ↑ conc, 24 h RT 36.86 7.62 91.24 20.67 61.63 1:15.6 
O 5 x ↑ conc, 24 h RT 33.45 6.18 82.80 18.48 50.02 1:19.3 
H 2 h 60 ˚C, 22 h RT 6.88 1.33 83.41 19.33 10.56 1:90.2 
J 2 h 60 ˚C, 22 h RT 6.84 1.95 84.44 28.51 15.78 1:61.0 
N 2 h 60 ˚C, 22 h RT 6.54 1.47 80.70 22.45 11.87 1:81.1 
B 1 h RT, 2 h 60 ˚C 7.02 1.08 82.76 15.00 8.09 1:118.5 
L 1 h RT, 2 h 60 ˚C 6.80 1.28 83.95 18.82 10.36 1:93.0 
P 1 h RT, 2 h 60 ˚C 6.04 1.11 74.57 18.38 9.98 1:107.2 
D 24 h RT 7.50 1.33 86.21 17.73 9.96 1:96.2 
E 24 h RT 6.58 0.96 80.24 14.59 7.62 1:125.0 
I 24 h RT 7.17 1.67 88.52 23.29 13.51 1:71.3 
M 24 h RT 6.55 1.29 80.86 19.69 10.44 1:92.3 
RT = room temperature 
↑ = increase in 
GEMCITABINE CONTAINING LIPOSOMES 
RESULTS AND DISCUSSION 
 
HILDE GRAVEM 2006  
67 
6.6.2.1 Incubation conditions and interpretation of the results: 
The samples were incubated according to the conditions listed in Table 21. All incubation 
conditions were run in triplicates except the preliminary runs A, C and F, which were run only 
once.  
 
Using equation 6, a recovery range of 74.57 % to 91.24 % of the added dFdC was obtained by 
HPLC for the actively loaded samples. Taking into account eventual preparation errors during 
this rather complicated multi-step procedure, this appears acceptable. As seen from Table 22 
the recovery within parallels has a SD ranging from 1.93 to 5.11. Table 22 also lists the mean 
parallel values of other calculated parameters. 
 
 















5x ↑ conc, 24 h RT 6.11 ± 1.55 86.60 ± 4.28 17.34 ± 4.02 49.18 ± 12.89 20.70 ± 5.40 
2 h 60 ˚C, 22 h RT 1.58 ± 0.33 82.85 ± 1.93 23.43 ± 4.67 12.74 ± 2.72 77.40 ± 14.90 
1 h RT, 2 h 60 ˚C 1.16 ± 0.11 80.43 ± 5.11 17.40 ± 2.09 9.14 ± 1.14 106.23 ± 12.80 
24 h RT 1.31 ± 0.29 83.96 ± 4.05 18.83 ± 3.64 10.38 ± 2.42 96.20 ± 22.10 
RT = room temperature 
↑ = increased 
 
 
The effect of incubation time, incubation temperature and concentration of dFdC on loading 
was compared for the actively loaded liposomes in three different ways. Firstly, encapsulation 
efficiencies were compared since they reveal to what extent added dFdC got encapsulated into 
liposomes. Secondly, the ratio of encapsulated dFdC to encapsulated ammonium sulphate was 
examined. This ratio yields information about the efficiency of loading as well as to what 
extent the gradient was utilised for encapsulation. Finally, the theoretical amount of 
encapsulated dFdC with respect to the theoretical amount of lipid in the liposome dispersion 
was investigated in order to evaluate the quality of the liposomes as drug carriers independent 
of the lipid amount, and the loading method used. 
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Encapsulation efficiency: 
The resultant encapsulation efficiencies of the active loaded samples are listed in Table 21 
and Table 22. The EE was ranging from approximately 3 % to 28 %. In general these values 
are low as compared to results gained with other drug compounds described in literature. For 
doxorubicin, an EE close to 100% is described. (24) This may have different reasons. Firstly, 
our conditions for loading may still be suboptimal despite some attempts for achieving 
improvements. Secondly, doxorubicin does upon active loading readily form precipitates 
inside the liposomes. Precipitation of the drug leads to a more favourable concentration 
gradient and in addition, it immobilises the drug and prevents leakage. The rather wide 
fluctuation seen between parallels and the rather small differences in mean encapsulation 
efficiencies between the different conditions makes it difficult to see relevant differences 
between the different conditions.  
 
Relationship between the amount of encapsulated dFdC and the amount of encapsulated 
ammonium sulphate: 
All the parallels with approximately 7 µmol dFdC appear to have similar ratios of roughly 10 
%, i.e. the entrapped amount of dFdC equals about one tenth of the entrapped ammonium 
sulphate amount on a molar basis. A five-fold increase in the concentration of dFdC as 
compared to other samples yielded a higher ratio of 49.18 ± 12.89 %, i.e. the entrapped 
amount of dFdC reached about half of the entrapped ammonium sulphate amount on a molar 
basis. It remains to be tested in future studies whether a further increase in dFdC would have 
given even better ratios. 
 
Interpretation of dFdC:lipid ratios: 
It is evident that entrapment of dFdC is dependent upon the incubation factors tested. 
Concentration seems to be the variable affecting the loading to the greatest extent. By a five 
fold increase in the added amount of dFdC to the samples, the loaded amount escalates to an 
almost five fold increase in the percentage relationship between dFdC and lipid. It is, 
however, not investigated whether the amount would increase proportionally with a further 
increase in concentration. 
 
The sample designated A (incubation for three hours at room temperature) revealed an almost  
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five fold lower amount of encapsulated dFdC than sample C (incubation for 2 hours and 45 
minutes at room temperature and 15 minutes at 60°C) and the samples D, E, I and M 
(incubation for 24 hours at room temperature). The active loading process thus appeared to be 
not yet completed after three hours at room temperature, whereas brief warming (15 minutes 
60°C) or alternatively incubation for 24 hours at room temperature led to the same result. 
Sample F (incubation for 48 hours) showed a similar encapsulation as samples incubated for 
24 hours in room temperature. The process thus seems to be completed after 24 hours at room 
temperature. An incubation time of 24 hours seems reasonable in order to maximise loading. 
Samples C on one hand and samples B, L and P on the other hand, which were incubated for 
different periods at 60°C (15 minutes and two hours, respectively) contained approximately 
the same amount of dFdC. A longer warming period, beyond 15 minutes, seems not to 
improve loading. The results from sample F indicated that exceeding a loading time of 24 
hours did not increase loading. A shorter incubation time is characterised by a smaller amount 
of entrapped dFdC, and is therefore reducing loading. Correspondingly, Haran et al found that 
increasing the temperature was facilitating the loading. (24) However, it has not been 
established whether a longer incubation time than two hours at 60 ˚C would facilitate loading. 
 
The samples with a five fold increase in concentration were the only samples where the added 
amount of dFdC exceeded the entrapped amount of ammonium sulphate within the liposomes 
and could therefore in theory utilise the ammonium sulphate gradient to the full extent 
assuming one mol of dFdC equals one mol of ammonium sulphate. According to this 
assumption, these samples made use of only approximately 50 percent of the gradient. Haran 
et al were measuring the concentration of ammonia diffusing through the lipid membrane. 
(24) They found a ratio of 4:1 between released ammonia and drug (doxorubicin) uptake. In 
these experiments the release of ammonia was never measured. Hence, the ratio between 
ammonia and dFdC and thereby the required ammonium sulphate per dFdC is unknown. 
 
6.6.2.2 Comparison of active and passive loading 
The recovery of the passive loaded sample was larger compared to the active loaded parallels 
for an inexplicable reason. The passive loaded liposomes had an EE of 20.71 whereas the 
active loaded parallels had a mean EE ranging from 17.34 to 23.43. The small difference in 
EE does not give any information in comparing the techniques since the concentration of 
dFdC and lipids in the two different methods were different. The VPG used for passive 
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loading was prepared from a concentration of 40 % lipids whereas the liposome dispersion 
used for active loading had an original concentration of 10 %. This is important since an 
increased lipid concentration will increase the encapsulated volume and thereby automatically 
the encapsulated amount of a substance. There are more lipids in the passively loaded sample 
compared to the active loaded sample, thus reinforcing the importance of comparing the 
molar ratio between dFdC and the lipids of the different loading techniques. 
 
137.5 moles of E-80 had to be present in order to passively encapsulate one mol of dFdC. For 
encapsulating one mol of dFdC the active method required between 15.6 and 551.7 moles 
(20.7–106.2 for parallels) of E-80. This means the liposomes in all the different active loaded 
parallels showed a greater loading capacity, compared to the passive loaded sample. The 
active loaded parallel incubated for 24 hours with a five-fold increase in concentration had the 
best ratio of 20.7 and thus the greatest loading capacity.  
 
In order to achieve this same ratio of 20.7 between dFdC and lipids, an EE of 91.8 % would 
theoretically be required for passively loaded 40 % VPG dispersion composed of E-80 in 
order to achieve the same ratio. The literature, however, describes an EE of only 33.2 % (15) 
and this means the active loaded liposomes had an even greater loading capacity than the 
VPG described in the literature. 
 
6.7 Stability of dFdC encapsulated liposomes 
It was investigated how long the liposomes could retain their amount of encapsulated dFdC in 
order to evaluate the stability of the liposome membranes. High stability is important in order 
to achieve a long shelf life of a product. 
 
Sample O, displaying a large amount of encapsulated dFdC, was chosen for the stability test. 
Samples where the external dFdC was already separated from the liposomes on the SEC 
column were further incubated in a fridge for 24 to 72 hours. After appropriate incubation 
time, the samples were run through the SEC column for a second time in order to remove 
dFdC leakage through the liposome membrane during incubation. Upon destruction of 
liposomes with triton solution, the solution was injected into HPLC for dFdC quantification. 
The results from the stability tests can be seen in Table 23.  
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Mean amount of dFdC in triplicates (ng/ml) 
0 h 542.3 
24 h 109.7* 
48 h N/A 
72 h N/A 
*) The dilution step from running the sample through the ion exchange column twice is accounted for.  
 
 
The results reveal 20.2 % of dFdC was retained within the liposomes, that means 
approximately 80 % of dFdC was leaking out of the vesicles after 24 hours. After 48 to 72 
hours, the remaining amount of dFdC inside the liposomes was negligible and could not be 
detected.  
 
These findings can be explained by three factors. Firstly, the liposomes were made solely of 
the lipid E-80. E-80 composes a lipid membrane not as tightly packed as membranes 
composed of other phospholipids or of phospholipids in combination with cholesterol. 
Secondly, the sink condition imposed upon the heavily diluted liposomes may have been a 
facilitating factor to the leakiness. And lastly, the literature describes an enhanced PC 
degradation upon loading liposomes with dFdC. (15) At what point this degradation initiates, 
is however not described. In addition, the effect on degradation of the larger amount of 
protonated dFdC within the liposomes is not discussed.  
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7 FUTURE REFERENCES 
At the present time, utilising this newly developed method for active loading of dFdC into 
liposomes reveals a greater loading capacity compared to passive loading. Unfortunately, the 
lipid membranes reveal poor stability due to dFdC leakage. However, a few alterations to the 
method could possibly further increase the dFdC: lipid ratio and increase the stability and 
thereby increase the usefulness of the encapsulation method: 
• By changing the lipid composing the membrane or by adding cholesterol the 
phospholipid membrane would be more densely packed preventing leakage of 
ammonium sulphate. This could lead to the establishment of a better gradient resulting 
in a greater influx of dFdC. 
• Appropriate adjustment of the pH of the external aqueous phase in the liposome 
dispersion will cause a further shift in the equilibrium of dFdC towards its basic form, 
increasing the encapsulation. 
• The lipid concentration of 40 % used for passive loading is much higher than the final 
lipid concentration of approximately 2 % for the active loading. Since a higher lipid 
concentration would yield the potential for a higher EE an increased lipid 
concentration of liposomes prepared for active loading could yield a larger 
entrapment. 
• According to Lipoid GmbH is E-80 composed of 80 - 85 % PC and does not display a 
tightly bound lipid bilayer. Therefore, in the combination with cholesterol, the lipid 
bilayer would become more tightly packed and thus have the potential to reduce 
leakiness and retain a high shelf life. 
• dFdC has shown to increase hydrolysis of phospholipids which again is enhanced by 
extremes of pH, as occurs during active loading. Therefore, it might be beneficial to 
formulate the liposomal dFdC as a vial kit, where dFdC is added to gradient 
containing liposomes in a hospital pharmacy setting just prior to administration. This 
will increase the shelf life of the product. Myocet (doxorubicin) is currently 
formulated as a vial kit utilising this approach.  
• To optimise loading the following conditions should be investigated: 
o The addition of larger amount of substance of dFdC 
o Increased loading time at 60 ˚C 
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8 CONCLUSION 
In order to investigate whether gemcitabine can be actively loaded into liposomes two goals 
had to be reached. Firstly, a method had to be established for generating liposomes with a 
transmembrane ammonium sulphate gradient. Secondly, a protocol for active loading had to 
be developed and the liposomes analysed in order to prove the validity of the loading method.  
 
The method for generating an appropriate ammonium sulphate transmembrane gradient 
comprised preparation of liposomes in ammonium sulphate solution and removing non-
entrapped ammonium sulphate by size exclusion chromatography. The transmembrane 
gradient was quantitatively measured upon lysis of the liposomes using conductivity 
measurements. 10 % triton solution was favoured as a dissolving agent due to ammonium 
sulphate precipitation upon disintegration with 96 % ethanol. The unacceptably high 
contribution of the triton solution to the overall conductivity of the lysed liposomes could be 
reduced by dialysis of the triton solution against excess distilled water prior to the 
disintegration. 
 
Active loading of liposomes due to the ammonium sulphate gradient was demonstrated 
qualitatively using acridine orange as a marker and followed quantitatively with gemcitabine. 
Variations in the loading protocol such as concentration of gemcitabine, temperature and time 
of incubation were shown to influence the active loading of gemcitabine. The best results 
were achieved with increased concentrations of gemcitabine and incubation at an elevated 
temperature. 
 
Actively loaded samples revealed a more efficient loading as compared to passively loaded 
vesicular phospholipid gels. However, the liposomal membranes composed of E-80 were not 
tight enough, as almost 80 % of encapsulated gemcitabine leaked out of the aqueous core 
within 24 hours.  
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Continuous High Pressure Filter Extrusion - pressures and translation factors 
 
Filter size (μm) Applied air pressure (bar) Resulting pressure over filter (bar) 
0.8 0.75 20 
0.4 0.75 20 
0.2 0.75 20 
0.1 1.50 60 
 
Filter size (μm) Applied air pressure (bar) Resulting pressure over filter (bar) 
0.8 0.75 0 
0.4 0.75 0 
0.2 1.00 25 
0.1 1.25 50 
 
Filter size (μm) Applied air pressure (bar) Resulting pressure over filter (bar) 
0.8 1 0 
0.4 N/A N/A 
0.2 1.5 20 
0.1 1.5 30 
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All results are from Gaussian distributions. 
1 E 80 - hand extruder 
2 E 80 - continuous high pressure filter extruder 
3 E 80/CH - hand extruder 
4 E 80/CH - continuous high pressure filter extruder 
5 VPG- high pressure homogenisation 
liposome 
preparation 
Mean SUV size 
of 
triplicate(nm) 






of channel no 1 
1 149.8 46.0 5 470 K 
2 106.7 33.8 5 295 K 
2 83.6 25.2 5 220 K 
2 69.9 22.3 5 77 K 
2 112.4 45.0 15 >1000 K 
2 96.7 37.4 15 >1000 K 
3 153.2 49.7 5 281 K 
4 153.0 74.9 5 660 K 
4 170.0 73.2 5 580 K 
4 173.2 75.1 5 580 K 
4 155.2 76.6 5 525 K 
4 160.7 73.8 5 550 K 
5 * * 45 >1000 K 
*)Homogenised VPG showed a NICOMP distribution and the mean diameter are listed below: 
 








Run 1 21.5 79.6 54.7 20.3 227.3 0.1 
Run 2 37.9 99.1 151.5 0.9 - - 
Run 3 35.6 98.7 136.8 1.3 - - 
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Appendix 3 
Calculations steps for quantifying pH and dissociation 
 
300 µl dFdC HCl solution (pH:2.9) is added to 5 ml liposome dispersion, giving a 
concentration of H+ ions: 
10-2.9 = 1.259 x 10-3 mol/l  
giving the amount of H+ in 300µl (3 x 10-4): 
1.259 x 10-3 mol/l * 3 x 10-4 l = 3.777 x 10-7 mol 
which leads to an amount in 5 ml: 
3.777 x 10-7 mol / 5 x 10-3 L = 7.554 x 10-5 mol/L 
Giving a pH of: 
-log 7.554 x 10-5  
pH = 4.12 
The pH of 4.12 is the pH of the outer aqueous phase. In determining this value, any influence 
of ammonium sulphate, glucose or lipids has not been accounted for. 
 
 
56 µl dFdC HCl solution (pH:2.9) is added to 5 ml liposome dispersion, giving a 
concentration of H+ ions: 
10-2.9 = 1.259 x 10-3 mol/l  
giving the amount of H+ in 56µl (5.6 x 10-5): 
1.259 x 10-3 mol/l * 5.6 x 10-5l = 7.050 x 10-8 mol 
which leads to an amount in 5 ml: 
7.050 x 10-8 mol / 5 x 10-3 L = 1.410 x 10-5 mol/L 
Giving a pH of: 
-log 1.410 x 10-5  
pH = 4.85 
The pH of 4.85 is the pH of the outer aqueous phase. In determining this value, any influence 
of ammonium sulphate, glucose or lipids has not been accounted for. 
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Henderson-Hasselbalch equation: 
pH= pKa - log ([BH+]/[B]) 
 
For: 
pH = 4.12 
pKa = 3.58 
4.12 = 3.58-log([BH+]/[B]) 
0.54 = -log([BH+]/[B]) 
-0.54 = log([BH+]/[B]) 
10-0.54 = ([BH+]/[B]) 
0.2884 = ([BH+]/[B]) 
[BH+] = 0.2884 * 100 % / 1.2884 
[BH+] = 22.4 % dissociated 
A protonation of 22.4 % of gemcitabine leaves 77.6 % in the uncharged form which can 




pH = 4.85 
pKa = 3.58 
4.85 = 3.58-log([BH+]/[B]) 
1.27 = -log([BH+]/[B]) 
-1.27 = log([BH+]/[B]) 
10-1.27 = ([BH+]/[B]) 
0.0537 = ([BH+]/[B]) 
[BH+] = 0.0537 * 100 % / 1.0537 
[BH+] = 5.1 % dissociated 
A protonation of 5.1 % of gemcitabine leaves 94.9 % in the uncharged form which can 
permeate the liposomal membrane. 
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Appendix 4 
Results from active loading 
Sample Conc run 1 
(ng/ml) 
Conc run 2 
(ng/ml) 
Mean conc of 
triplicate (ng/ml) 
Amount of dFdC 
in sample (μmol)
Amount dFdC added 
to sample (μmol) 
Amount (NH4)2SO4 
in sample (μmol) 
Amount of lipid in 
sample (μmol) 
AT1 601.9 598.1 
AT2 641.5 638.8 
AT3 636.2 636.1 
625.4 7.13 
AE1 22.2 22.1 
AE2 19.6 20.8 
AE3 19.0 18.5 
20.4 0.23 
8.7 13.4 128 
BT1 613.1 614.6 
BT2 646.7 648.2 
BT3 632.4 631.9 
631.1 7.2 
BE1 96.3 95.6 
BE2 90.1 89.6 
BE3 97.3 97.4 
94.4 1.08 
8.7 13.4 128 
CT1 620.4 620.9 
CT2 626.3 622.3 
CT3 636.0 634.8 
626.8 7.14 
CE1 101.9 102.6 
CE2 99.2 98.3 
99.8 1.14 
8.7 13.4 128 
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CE3 97.8 98.9 
DT1 664.7 668.1 
DT2 628.1 627.6 
DT3 686.3 645.2 
653.4 7.5 
DE1 115.0 114.5 
DE2 120.2 117.0 
DE3 115.6 116.7 
116.5 1.33 
8.7 13.4 128 
ET1 570.6 559.8 
ET2 578.2 576.1 
ET3 594.6 581.9 
576.9 6.58 
EE1 85.9 87.8 
EE2 84.0 84.1 
EE3 82.1 81.7 
84.3 0.96 
8.2 12.6 120 
FT1 637.0 611.2 
FT2 650.6 626.0 
FT3 634.5 619.8 
629.9 7.18 
FE1 104.6 102.1 
FE2 111.0 102.7 
FE3 109.8 103.3 
105.6 1.20 
8.2 12.6 120 
GT1 3046.1 3006.4 
GT2 3126.7 3100.1 
3077.5 35.08 40.9 12.6 120 
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GT3 3107.6 3078.1 
GE1 397.5 394.1 
GE2 398.5 392.3 
GE3 400.6 396.1 
396.5 4.52 
HT1 614.0 606.4 
HT2 613.1 606.1 
HT3 598.0 585.3 
603.8 6.88 
HE1 115.8 115.0 
HE2 116.4 115.7 
HE3 119.3 117.9 
116.7 1.33 
8.2 12.6 120 
IT1 633.3 604.2 
IT2 636.9 618.2 
IT3 615.5 664.7 
628.8 7.17 
IE1 142.4 144.5 
IE2 144.1 148.8 
IE3 150.8 148.1 
146.5 1.67 
8.1 12.4 119 
JT1 617.6 605.2 
JT2 593.9 582.4 
JT3 591.2 611.9 
600.4 6.84 
JE1 176.0 168.0 
JE2 162.5 169.6 
170.7 1.95 
8.1 12.4 119 
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JE3 170.9 177.4 
KT1 3246.9 3190.7 
KT2 3278.2 3232.6 
KT3 3180.9 3272.4 
3233.6 36.86 
KE1 687.8 660.7 
KE2 655.0 674.5 
KE3 662.1 670.7 
668.5 7.62 
40.4 12.4 119 
LT1 578.6 567.4 
LT2 619.4 615.2 
LT3 607.0 597.9 
596.4 6.80 
LE1 114.4 111.8 
LE2 108.7 107.6 
LE3 115.1 115.5 
112.2 1.28 
8.1 12.4 119 
MT1 582.4 583.2 
MT2 584.0 576.7 
MT3 562.3 558.8 
574.6 6.55 
ME1 148.4 117.6 
ME2 97.1 92.0 
ME3 114.5 109.8 
113.2 1.29 
8.1 12.4 119 
NT1 589.4 590.0 
NT2 574.4 576.8 
573.6 6.54 8.1 12.4 119 
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NT3 555.1 555.9 
NE1 126.3 126.0 
NE2 128.2 127.6 
NE3 131.9 131.8 
128.6 1.47 
OT1 3005.4 2930.7 
OT2 2926.0 2835.466 
OT3 2971.7 2935.893 
2934.2 33.45 
OE1 567.1 545.903 
OE2 542.1 493.359 
OE3 556.7 548.584 
542.3 6.18 
40.4 12.4 119 
PT1 587.6 587.579 
PT2 595.9 597.365 
PT3 607.1 606.678 
529.6 6.04 
PE1 93.6 94.044 
PE2 94.8 95.894 
PE3 102.5 102.918 
97.3 1.11 
8.1 12.4 119 
Loading conditions: 
A = 3 h at RT 
B, L, P = 1 h at RT and 2 h at 60 ˚C 
C = 2h 45 min at RT and 15 min at 60 ˚C 
D, E, I, M = 24 h at RT 
F = 48 h RT 
G, K, O = 5 x increased concentration, 24 h at RT 
H, J, N =2 h at 60 °C and 22 h at RT 
